

## **A Mendelian randomization analysis of circulating lipid traits and breast cancer risk**

Alicia Beeghly-Fadiel<sup>1‡</sup>, Nikhil K Khankari<sup>1‡</sup>, Ryan J Delahanty<sup>2</sup>, Xiao-Ou Shu<sup>1</sup>, Yingchang Lu<sup>1</sup>, Marjanka K Schmidt<sup>3,4</sup>, Kyriaki Michailidou<sup>5,6</sup>, Manjeet K Bolla<sup>5</sup>, Qin Wang<sup>5</sup>, Joe Dennis<sup>5</sup>, ABCTB Investigators<sup>7</sup>, Irene L Andrulis<sup>8</sup>, Natalia N Antonenkova<sup>9</sup>, Hoda Anton-Culver<sup>10</sup>, Volker Arndt<sup>11</sup>, Kristan J Aronson<sup>12</sup>, Paul L Auer<sup>13,14</sup>, Myrto Barrdahl<sup>15</sup>, Caroline Baynes<sup>16</sup>, Laura E Beane Freeman<sup>17</sup>, Matthias W Beckmann<sup>18</sup>, Sabine Behrens<sup>19</sup>, Javier Benitez<sup>20,21</sup>, Marina Bermisheva<sup>22</sup>, Carl Blomqvist<sup>23</sup>, Natalia V Bogdanova<sup>9,24,25</sup>, Stig E Bojesen<sup>26–28</sup>, Bernardo Bonanni<sup>29</sup>, Judith S Brand<sup>30</sup>, Hiltrud Brauch<sup>31–33</sup>, Hermann Brenner<sup>11,33,34</sup>, Louise Brinton<sup>35</sup>, Annegien Broeks<sup>3</sup>, Sara Y Brucker<sup>36</sup>, Thomas Brüning<sup>37</sup>, Barbara Burwinkel<sup>38,39</sup>, Qiuyin Cai<sup>1</sup>, Trinidad Caldés<sup>40</sup>, Federico Canzian<sup>41</sup>, Brian D Carter<sup>42</sup>, Jose E Castelao<sup>43</sup>, Jenny Chang-Claude<sup>19,44</sup>, Ting-Yuan David Cheng<sup>45</sup>, Christine L Clarke<sup>46</sup>, Fergus J Couch<sup>47</sup>, Angela Cox<sup>48</sup>, Simon S Cross<sup>49</sup>, Julie M Cunningham<sup>47</sup>, Kamila Czene<sup>30</sup>, Mary B Daly<sup>50</sup>, Peter Devilee<sup>51,52</sup>, Kimberly F Doherty<sup>53</sup>, Thilo Dörk<sup>25</sup>, Isabel dos-Santos-Silva<sup>54</sup>, Martine Dumont<sup>55</sup>, Miriam Dwek<sup>56</sup>, H Shelton Earp<sup>57</sup>, Diana M Eccles<sup>58</sup>, Heather Eliassen<sup>59,60</sup>, Christoph Engel<sup>61,62</sup>, Mikael Eriksson<sup>30</sup>, Peter A Fasching<sup>18,63</sup>, Jonine Figueroa<sup>35,64,65</sup>, Olivia Fletcher<sup>66</sup>, Henrik Flyger<sup>67</sup>, Lin Fritschi<sup>68</sup>, Manuela Gago-Dominguez<sup>69,70</sup>, Susan M Gapstur<sup>42</sup>, Montserrat García-Closas<sup>35</sup>, D Gareth Evans<sup>71,72</sup>, Mia M Gaudet<sup>42</sup>, Graham G Giles<sup>73,74</sup>, Mark S Goldberg<sup>75,76</sup>, David E Goldgar<sup>77</sup>, Anna González-Neira<sup>20</sup>, Grethe I Grenaker Alnæs<sup>78</sup>, Pascal Guénel<sup>79</sup>, Lothar Haeberle<sup>18</sup>, Eric Hahnen<sup>80–82</sup>, Christopher A Haiman<sup>83</sup>, Niclas Håkansson<sup>84</sup>, Emily Hallberg<sup>85</sup>, Ute Hamann<sup>86</sup>, Patricia Harrington<sup>16</sup>, Andreas Hartkopf<sup>32</sup>, Alexander Hein<sup>18</sup>, Belynda Hicks<sup>87</sup>, Peter Hillemanns<sup>25</sup>, Antoinette Hollestelle<sup>88</sup>, Maartje J Hooning<sup>88</sup>, Robert N Hoover<sup>35</sup>, Anthony Howell<sup>89</sup>, Guanmengqia Huang<sup>86</sup>, kConFab/AOCS Investigators<sup>90,91</sup>, Anna Jakubowska<sup>92</sup>, Wolfgang Janni<sup>93</sup>, Esther M John<sup>94–96</sup>, Nichola Johnson<sup>66</sup>, Kristine Jones<sup>87</sup>, Audrey Jung<sup>19</sup>, Rudolf Kaaks<sup>19</sup>, Siddhartha Kar<sup>16</sup>, Vesa Kataja<sup>97,98</sup>, Elza Khusnutdinova<sup>22,99</sup>, Cari M Kitahara<sup>35</sup>, Julia A Knight<sup>100,101</sup>, Yon-Dschun Ko<sup>102</sup>, Veli-Matti Kosma<sup>98,103,104</sup>, Stella Koutros<sup>17</sup>, Vessela N Kristensen<sup>78,105,106</sup>, Tabea Kuhl<sup>45</sup>, France Labrèche<sup>107</sup>, Diether Lambrechts<sup>108,109</sup>, Flavio Lejbkovicz<sup>110</sup>, Annika Lindblom<sup>111</sup>, Sara Lindström<sup>112,113</sup>, Martha S Linet<sup>35</sup>, Jolanta Lissowska<sup>114</sup>, Wing-Yee Lo<sup>31,32</sup>, Sibylle Loibl<sup>115</sup>, Jirong Long<sup>1</sup>, Jan Lubinski<sup>92</sup>, Craig Luccarini<sup>16</sup>, Michael P Lux<sup>18</sup>, Robert J MacInnis<sup>73,74</sup>, Tom Maishman<sup>58,116</sup>, Ivana Maleva Kostovska<sup>117</sup>, Arto Mannermaa<sup>98,103,104</sup>, JoAnn E Manson<sup>60,118</sup>, Sara Margolin<sup>119</sup>, Frederik

Marme<sup>38</sup>, Dimitrios Mavroudis<sup>120</sup>, Usha Menon<sup>121</sup>, Jeffery Meyer<sup>47</sup>, Pooja Middha<sup>19</sup>, Susan L Neuhausen<sup>122</sup>, Heli Nevanlinna<sup>123</sup>, Patrick Neven<sup>124</sup>, William T Newman<sup>71,72</sup>, Sune F Nielsen<sup>26,27</sup>, Børge G Nordestgaard<sup>26-28</sup>, Olufunmilayo I Olopade<sup>125</sup>, Andrew F Olshan<sup>126</sup>, Janet E Olson<sup>85</sup>, Håkan Olsson<sup>127</sup>, Curtis Olsword<sup>85</sup>, Nick Orr<sup>66</sup>, Charles M Perou<sup>128</sup>, Julian Peto<sup>54</sup>, Mila Pinchev<sup>110</sup>, Dijana Plaseska-Karanfilska<sup>117</sup>, Ross Prentice<sup>13</sup>, Nadege Presneau<sup>56</sup>, Katri Pylkäs<sup>129,130</sup>, Brigitte Rack<sup>131</sup>, Paolo Radice<sup>132</sup>, Gadi Rennert<sup>110</sup>, Hedy S Rennert<sup>110</sup>, Valerie Rhenius<sup>16</sup>, Atocha Romero<sup>40,133</sup>, Jane Romm<sup>53</sup>, Emmanouil Saloustros<sup>134</sup>, Dale P Sandler<sup>135</sup>, Elinor J Sawyer<sup>136</sup>, Rita K Schmutzler<sup>80-82</sup>, Andreas Schneeweiss<sup>38,137</sup>, Frederick Schumacher<sup>83</sup>, Rodney J Scott<sup>138,139</sup>, Christopher Scott<sup>85</sup>, Mitul Shah<sup>16</sup>, Martha J Shrubsole<sup>1</sup>, Ann Smeets<sup>124</sup>, Melissa C Southey<sup>140</sup>, John J Spinelli<sup>141,142</sup>, Jennifer Stone<sup>74,143</sup>, Harald Surowy<sup>38,39</sup>, Anthony Swerdlow<sup>144,145</sup>, Rulla Tamimi<sup>59,60,112</sup>, Jack A Taylor<sup>135,146</sup>, Mary Beth Terry<sup>147</sup>, Daniel C Tessier<sup>148</sup>, Kathrin Thöne<sup>45</sup>, Madeleine M A Tilanus-Linthorst<sup>88</sup>, Rob A E M Tollenaar<sup>149</sup>, Ian Tomlinson<sup>150</sup>, Diana Torres<sup>86,151</sup>, Melissa A Troester<sup>126</sup>, Thérèse Truong<sup>79</sup>, Hans-Ulrich Ulmer<sup>152</sup>, Michael Untch<sup>153</sup>, Celine Vachon<sup>85</sup>, David Van Den Berg<sup>83</sup>, Elke M van Veen<sup>71,72</sup>, Daniel Vincent<sup>148</sup>, Clarice R Weinberg<sup>154</sup>, Camilla Wendt<sup>119</sup>, Alice S Whittemore<sup>95,96</sup>, Hans Wildiers<sup>124</sup>, Robert Winqvist<sup>129,130</sup>, Alicja Wolk<sup>84</sup>, Lucy Xia<sup>83</sup>, Xiaohong R Yang<sup>35</sup>, Argyrios Ziogas<sup>10</sup>, Elad Ziv<sup>155</sup>, Drakoulis Yannoukakos<sup>156</sup>, Alison M Dunning<sup>16</sup>, Paul D P Pharoah<sup>5,16</sup>, Peter Kraft<sup>60,112</sup>, Georgia Chenevix-Trench<sup>91</sup>, Roger L Milne<sup>73,74</sup>, Per Hall<sup>30</sup>, Jacques Simard<sup>55</sup>, David J Hunter<sup>60,112</sup>, Douglas F Easton<sup>5,16</sup>, and Wei Zheng<sup>1\*</sup>

#### **Affiliations:**

1. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
2. Tenet Healthcare, 20 Burton Hills Blvd, Suite 200, Nashville, TN 37215, USA.
3. Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

4. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.
5. Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
6. Department of Electron Microscopy/Molecular Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
7. Australian Breast Cancer Tissue Bank, Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
8. Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Department of Molecular Genetics, The University of Toronto, Ontario, Canada.
9. N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.
10. Department of Epidemiology, University of California Irvine, Irvine, CA, USA.
11. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
12. Department of Public Health Sciences, and Cancer Research Institute, Queen's University, Kingston, ON, Canada.
13. Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
14. Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
15. Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
16. Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
17. Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

18. Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
19. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
20. Human Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid, Spain.
21. Centro de Investigación en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
22. Institute of Biochemistry and Genetics, Ufa Scientific Center of Russian Academy of Sciences, Ufa, Russia.
23. Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
24. Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
25. Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
26. Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
27. Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
28. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
29. Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan, Italy.
30. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
31. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
32. University of Tübingen, Tübingen, Germany.
33. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
34. Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
35. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.

36. Department of Women's Health, University of Tübingen, Tübingen, Germany.
37. Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Bochum, Germany.
38. Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.
39. Molecular Epidemiology Group, C080, German Cancer Research Center (DKFZ), Heidelberg, Germany.
40. Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
41. Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
42. Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
43. Oncology and Genetics Unit, Instituto de Investigación Biomedica (IBI) Galicia Sur, Xerencia de Xestión Integrada de Vigo-SERGAS, Vigo, Spain.
44. Research Group Genetic Cancer Epidemiology, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
45. Division of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
46. Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
47. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
48. Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
49. Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, UK.
50. Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
51. Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
52. Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.

53. Center for Inherited Disease Research (CIDR), Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
54. Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
55. Genomics Center, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec City, QC, Canada.
56. Department of Biomedical Sciences, Faculty of Science and Technology, University of Westminster, London, UK.
57. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
58. Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
59. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
60. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
61. Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
62. LIFE - Leipzig Research Centre for Civilization Diseases, University of Leipzig, Leipzig, Germany.
63. David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, USA.
64. Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh, UK.
65. Cancer Research UK Edinburgh Centre, Edinburgh, UK.

66. The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
67. Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
68. School of Public Health, Curtin University, Perth, Western Australia, Australia.
69. Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.
70. Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
71. Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
72. Manchester Centre for Genomic Medicine, St. Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
73. Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
74. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
75. Department of Medicine, McGill University, Montréal, QC, Canada.
76. Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University, Montréal, QC, Canada.
77. Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.
78. Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.

79. Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif, France.
80. Center for Hereditary Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany.
81. Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany.
82. Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
83. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
84. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
85. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
86. Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
87. Cancer Genomics Research Laboratory (CGR), Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research, Rockville, MD, USA.
88. Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
89. Institute of Cancer studies, University of Manchester, Manchester, UK.
90. Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
91. Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
92. Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
93. Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
94. Department of Epidemiology, Cancer Prevention Institute of California, Fremont, CA, USA.



95. Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
96. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
97. Cancer Center, Kuopio University Hospital, Kuopio, Finland.
98. Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland.
99. Department of Genetics and Fundamental Medicine, Bashkir State University, Ufa, Russia.
100. Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
101. Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
102. Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany.
103. Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.
104. Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland.
105. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
106. Department of Clinical Molecular Biology, Oslo University Hospital, University of Oslo, Oslo, Norway.
107. Institut de recherche Robert-Sauvé en santé et en sécurité du travail, Montréal, Québec, Canada.
108. VIB Center for Cancer Biology, VIB, Leuven, Belgium.
109. Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium.
110. Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.

111. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
112. Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
113. Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, USA.
114. Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland.
115. German Breast Group, GmbH, Neu Isenburg, Germany.
116. Southampton Clinical Trials Unit, Faculty of Medicine , University of Southampton, Southampton, UK.
117. Research Centre for Genetic Engineering and Biotechnology 'Georgi D. Efremov' , Macedonian Academy of Sciences and Arts, Skopje, Republic of Macedonia.
118. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
119. Department of Oncology - Pathology, Karolinska Institutet, Stockholm, Sweden.
120. Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Greece.
121. Gynaecological Cancer Research Centre, Women's Cancer, Institute for Women's Health, University College London, London, UK.
122. Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.
123. Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
124. Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
125. Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL, USA.

126. Department of Epidemiology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
127. Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden.
128. Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
129. Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.
130. Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre Oulu, Oulu, Finland.
131. Department of Gynecology and Obstetrics, Ludwig-Maximilians University of Munich, Munich, Germany.
132. Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto Nazionale dei Tumori (INT), Milan, Italy.
133. Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
134. Hereditary Cancer Clinic, University Hospital of Heraklion, Heraklion, Greece.
135. Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA.
136. Research Oncology, Guy's Hospital, King's College London, London, UK.
137. National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
138. Division of Molecular Medicine, Pathology North, John Hunter Hospital, Newcastle, New South Wales, Australia.
139. Discipline of Medical Genetics, School of Biomedical Sciences and Pharmacy, Faculty of Health, University of Newcastle, Callaghan, New South Wales, Australia.

140. Department of Pathology, The University of Melbourne, Melbourne, Victoria, Australia.
141. Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.
142. School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
143. The Curtin UWA Centre for Genetic Origins of Health and Disease, Curtin University and University of Western Australia, Perth, Western Australia, Australia.
144. Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
145. Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
146. Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA.
147. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
148. McGill University and Génome Québec Innovation Centre, Montréal, QC, Canada.
149. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
150. Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
151. Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.
152. Frauenklinik der Stadtklinik Baden-Baden, Baden-Baden, Germany.
153. Department of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, Berlin, Germany.
154. Biostatistics Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA.
155. Department of Medicine, Institute for Human Genetics, UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
156. Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, Greece.

**Running title:** Lipid traits and breast cancer risk

**‡ Contributed equally to this work**

**\*To Whom Correspondence Should be Addressed:**

Wei Zheng, M.D., Ph.D.

Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center

Vanderbilt University School of Medicine

2525 West End Avenue, 8th Floor, Nashville, TN 37203-1738, USA

Phone: (615) 936-0682 Fax: (615) 343-0719

E-mail: [wei.zheng@vanderbilt.edu](mailto:wei.zheng@vanderbilt.edu)

## **SUMMARY** (234/250 words)

**Background:** Conventional epidemiological studies have evaluated associations between circulating lipid levels and breast cancer risk, but results have been inconsistent. As Mendelian randomization analyses may provide evidence for causal inference, we sought to evaluate potentially unbiased associations between breast cancer risk and four genetically predicted lipid traits.

**Methods:** Previous genome-wide association studies (GWAS) identified 162 variants associated with high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), triglycerides, and total cholesterol. We used these variants to construct weighted genetic scores (wGSs) for a total of 101 424 breast cancer cases and 80 253 controls of European ancestry from the Breast Cancer Association Consortium (BCAC). Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for associations between per standard deviation increase in genetically predicted lipid traits and breast cancer risk. Additional Mendelian randomization analysis approaches and sensitivity analyses were conducted to assess pleiotropy and instrument validity.

**Results:** Corresponding to approximately 15 mg/dL, one standard deviation increase in genetically predicted HDL-C was associated with a 12% increased breast cancer risk (OR: 1.12, 95% CI: 1.08-1.16). Findings were consistent after adjustment for breast cancer risk factors and were robust in several sensitivity analyses. Associations with genetically predicted triglycerides and total cholesterol were inconsistent, and no association for genetically predicted LDL-C was observed.

**Conclusions:** This study provides strong evidence that circulating HDL-C may be associated with an increased risk of breast cancer while LDL-C may not be related to breast cancer risk.

**Key Words:** breast cancer; lipids; cholesterol; genetics; Mendelian randomization; instrumental variable; epidemiology

**Key Messages:**

- We conducted a large Mendelian randomization analysis to provide unbiased estimates of association for four lipid traits among 181,677 European-ancestry women from the Breast Cancer Association Consortium.
- One standard deviation increase (representing approximately 15 mg/dL increase) in genetically predicted high density lipoprotein-cholesterol (HDL-C) was associated with a 12% increased risk of breast cancer, while no consistent associations were found with low density lipoprotein-cholesterol, triglycerides, or total cholesterol.
- This study strongly suggests that circulating HDL-C levels may influence breast cancer susceptibility.

**Manuscript word count:** 2,894/3,000 words

## INTRODUCTION

Circulating lipids, including high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), triglycerides, and total cholesterol, have long been hypothesized to influence the risk of breast, colorectal, and other common cancers.<sup>1-4</sup> Early prospective cohort studies reported inverse associations for total cholesterol and cancer risk.<sup>2-4</sup> However, these findings could be due to reverse causation, where disease development or progression leads to lower circulating cholesterol levels years before disease diagnosis.<sup>5-7</sup> It is also possible that confounding factors, such as smoking, alcohol consumption, and socioeconomic status, may have biased associations reported in prior epidemiologic studies.<sup>8,9</sup>

The role of HDL-C in disease risk is controversial. Although it is an established risk factor for coronary heart disease,<sup>10</sup> large Mendelian randomization analyses have suggested that the association between low HDL-C and heart disease may not be causal.<sup>11,12</sup> Furthermore, clinical trials designed to increase circulating HDL-C levels pharmacologically have not demonstrated overall benefits in heart disease prevention.<sup>13,14</sup> With regard to breast cancer, multiple studies have found inverse associations between HDL-C and risk.<sup>15,16</sup> Contrary to these findings, HDL-C was associated with increased breast cancer risk when repeated serum lipid measures were evaluated.<sup>17</sup> Given the current controversy regarding the association between circulating lipid traits and cancer in general, and with breast cancer in particular, this finding has faced skepticism.<sup>18</sup>

Due to methodological limitations such as reverse causation and confounding, it is unlikely that conventional observational studies can resolve the long-standing debate about the role of circulating lipids in breast cancer development. Mendelian randomization analyses can



potentially overcome many of the limitations inherent in conventional epidemiologic studies and may provide evidence for causal inference. Taking advantage of the random assortment of alleles that occurs during gametogenesis, thereby resembling randomized clinical trials, Mendelian randomization analysis uses genetic data to estimate associations that unlikely to be biased due to confounding.<sup>19</sup> To date, genome-wide association studies (GWAS) have linked circulating lipid traits to at least 157 genetic loci.<sup>20,21</sup> We used these lipid-associated variants to create instrumental variables in a Mendelian randomization analysis to evaluate shared genetic components and the association between circulating lipids and breast cancer risk.

## **METHODS**

### **Study Population**

The Breast Cancer Association Consortium (BCAC) is an international collaboration initiated in 2005 to study genetic susceptibility to breast cancer. First, we included individual-level epidemiologic and genetic data from 62 846 breast cancer cases and 43 207 healthy controls of European ancestry from 67 BCAC studies; genetic data included more than 500 000 variants from a custom OncoArray platform that was designed to provide dense coverage across known cancer susceptibility loci as well as common variants.<sup>22</sup> Second, we included independent data from 38 578 cases and 37 046 BCAC controls that were genotyped on the Illumina iSelect genotyping Collaborative Oncological Gene-Environment Study (iCOGS) array (<http://ccge.medschl.cam.ac.uk/research/consortia/icogs/>).<sup>23</sup> Demographic and selected patient characteristic were harmonized across BCAC studies according to a standardized

protocol. All BCAC studies were approved by relevant institutional review boards, and all participants provided written informed consent.

### **Variant Genotyping, Imputation, and Selection**

Genetic variants associated with lipid traits were selected from the Global Lipids Genetics Consortium. The first lipid-trait GWAS included approximately 100 000 subjects of European ancestry and identified 102 genetic variants in 95 loci.<sup>20</sup> The second GWAS, conducted among 188 577 subjects predominantly of European ancestry, identified 62 additional variants for a total of 157 lipid associated loci.<sup>21</sup> Of the 164 variants in these loci, 87 were genotyped by OncoArray and 75 were imputed with high information quality scores (mean  $r^2=0.98$ , range=0.86-0.99). In iCOGS data, 39 selected variants were genotyped, and 123 were successfully imputed (mean  $r^2=0.82$ , range=0.35-0.99). Two variants (rs2247056 and rs3177928) were not imputed in either dataset, providing a total of 162 in our analysis (**Supplementary Table 1**). Except for two variants (rs2814982 and rs2814944) in moderate linkage disequilibrium (LD;  $r^2 =0.51$ ), all included variants were independent ( $r^2 < 0.1$ ). Because rs2814982 was associated with total cholesterol and rs2814944 was associated with HDL-C, both were retained in our analysis, as they were not both included together in any one instrumental variable. Thus, based on published GWAS, instrumental variables for HDL-C, LDL-C, triglycerides, and total cholesterol included 74, 57, 43, and 74 variants, respectively.

### **Mendelian Randomization Analyses**

Our primary analysis used individual-level data from BCAC iCOGS and OncoArray to generate weighted-genetic scores (wGSs) for four lipid traits (HDL-C, LDL-C, triglycerides, and total cholesterol). For each lipid trait, we constructed instrumental variables as follows:  $wGS = \sum_{i=1}^n \beta_{gx} * \alpha_i$ , where  $\beta_{gx}$  represents the effect for the genetic variant ( $g$ ) associated with an increase in lipid levels ( $x$ ),  $\alpha_i$  is effect allele dosage for each genetic variant (ranging from 0 to 2 for each individual), for  $n$  genetic variants from the Global Lipids Genetics Consortium GWAS.<sup>20,21</sup>

Associations between wGSs and breast cancer risk factors were assessed using linear or logistic regression for continuous or categorical variables, respectively (**Supplementary Table 2**). Associations between lipid trait wGSs and breast cancer risk were estimated by odds ratios (ORs) and 95% confidence intervals (95% CIs) from unconditional logistic regression using individual level data. Analyses were conducted separately for BCAC participants with iCOGS and OncoArray data (**Supplementary Table 3**), and then combined by random-effects meta-analysis; Cochran's Q statistic was used to evaluate heterogeneity. Models were adjusted for age, principal components (PCs) for European ancestry (iCOGS: 6 PCs; OncoArray: 10 PCs), and either study site (iCOGS) or country (OncoArray), as previously described.<sup>22,24</sup> Additional adjustment included breast cancer risk factors that were associated with lipid trait wGSs. To reduce correlation between instrumental variables, we also constructed amended wGSs that included only genetic variants that were exclusively associated with HDL-C (54 variants), LDL-C (42 variants), or triglycerides (20 variants) at a genome-wide significance level (**Supplementary Table 4**); because total cholesterol includes other lipid traits, no such exclusive variant wGS was created.

We assessed effect measure modification by menopausal status, age (dichotomized at 50 years), and body mass index (dichotomized at 30 kg/m<sup>2</sup>) using likelihood ratio tests (LRT) for multiplicative interaction terms in nested models. Polytomous regression was employed to evaluate associations with estrogen receptor (ER) positive (+) and ER negative (-) breast cancer subtypes; tests of equivalence of beta coefficients across subtypes were used to evaluate heterogeneity.

### **Sensitivity Analyses**

In addition to individual-level analyses, we also conducted Mendelian randomization analysis using inverse-variance weighted summary statistics (**Supplementary Table 5**).<sup>25</sup> Three additional sensitivity analyses were used to assess the influence of genetic pleiotropy and validity of our genetic instruments. First, Egger regression was employed to evaluate the presence of directional pleiotropy by testing whether the intercept was statistically different from zero, and to estimate a bias-reduced Mendelian randomization estimate from the regression slope.<sup>26</sup> Second, a weighted multivariable regression-based approach was used to assess the influence of potential pleiotropic effects of genetic variants included in each instrument on other lipid traits; specifically, we regressed beta-coefficients for associations between genetic variants and breast cancer risk ( $\beta_{BC}$ ) on beta-coefficients between genetic variants and lipid traits (HDL-C:  $\beta_{HDL-C}$ , LDL-C:  $\beta_{LDL-C}$ , triglycerides:  $\beta_{TG}$ , and total cholesterol:  $\beta_{TC}$ ).<sup>27,28</sup> Third, we estimated associations using a weighted-median Mendelian randomization approach where we assumed that 50% of the variants included in each genetic instrument were invalid (i.e., did not meet at least one of the three assumptions necessary for a valid

instrumental variable); standard errors were estimated by bootstrapping and were subsequently used to calculate 95% CIs.<sup>29</sup> Analyses were completed using SAS (version 9.4), R (version 3.1.2), and Stata (version 12.1).

## RESULTS

One genetically predicted standard deviation increase in HDL-C, LDL-C, triglycerides, and total cholesterol was calculated to correspond to approximately 15, 37, 43, and 42 mg/dL increases, respectively. Associations between breast cancer risk factors and lipid trait wGSs were evaluated among all BCAC participants (**Supplementary Table 2**) and also among only controls (data not shown). Several associations were identified; however, the only consistent association across the two populations and genotyping platforms was between increasing age and lower total cholesterol (iCOGS  $P=4.0 \times 10^{-4}$  and OncoArray  $P=0.01$ ). Similarly, the only consistent association among controls was between increasing age and lower triglycerides (iCOGS  $P=0.04$  and OncoArray  $P=0.03$ ).

Associations for each standard deviation increase in genetically predicted lipid trait from iCOGS and OncoArray genotyped BCAC participants (**Supplementary Table 3**) were combined by random-effects meta-analysis (**Table 1**). HDL-C and total cholesterol were associated with increased breast cancer risk after meta-analysis of unadjusted regression models; however, only increased HDL-C levels were associated with increased breast cancer risk (OR: 1.12, 95% CI: 1.08-1.16) after adjustment for age, study site or country, and principal components for European ancestry. We also created instrumental variables with reduced correlation by using only 54, 42, and 20 exclusive genetic variants for HDL-C, LDL-C, and triglycerides, respectively

**(Supplementary Table 4)**. When repeating our primary analysis with these amended instruments, HDL-C wGS was associated with increased breast cancer risk only after multivariable adjustment (OR: 1.14, 95% CI: 1.07-1.22) (**Table 1**). On the contrary, the exclusive variant triglyceride wGS was not associated with breast cancer after multivariable adjustment (OR: 1.00, 95% CI: 0.86-1.16). Regardless of adjustment or whether initial or exclusive variants were included, the wGS for LDL-C was not associated with breast cancer risk.

**(Table 1 here)**

To examine differences in breast cancer associations by menopausal status, age, and BMI, we conducted stratified analyses; to examine differences in risk by ER status we employed polytomous regression (**Table 2**). No interaction by menopausal status, age or BMI were observed among iCOGS and Oncoarray genotyped participants for any lipid trait. For the HDL-C wGS, increased breast cancer risk was observed per one standard deviation increase among postmenopausal women (1.11, 95% CI: 1.05-1.17), women less than 50 years of age (1.17, 95% CI: 1.01-1.34), women age 50 or greater (1.11, 95% CI: 1.06-1.16), and non-obese (BMI<30 kg/m<sup>2</sup>) women (1.14, 95% CI: 1.08-1.20). Associations were also observed for both ER- (1.10, 95% CI: 1.03-1.18) and ER+ (1.11, 95% CI: 1.07-1.16) breast cancer risk. On the contrary, each standard deviation increase in triglycerides was associated with reduced breast cancer risk among postmenopausal women (OR: 0.93, 95% CI: 0.88-0.99), women age 50 or greater (OR: 0.93, 95% CI: 0.89-0.98), and non-obese women (OR: 0.90, 95% CI: 0.83-0.98); the association was also observed for ER+ breast cancer (OR: 0.91, 95% CI: 0.85-0.91). In these stratified analyses, total cholesterol was associated with breast cancer risk only among premenopausal women (OR: 1.08, 95% CI: 1.00-1.17).

**(Table 2 here)**

We conducted several sensitivity analyses to assess the validity of our instrumental variables (**Supplementary Table 5**). The inverse-variance weighted Mendelian randomization estimate using summary statistics<sup>25</sup> confirmed our initial findings: increased HDL-C was associated with increased breast cancer risk regardless of data source. On the contrary, triglycerides were associated with reduced breast cancer risk only in OncoArray data (OR: 0.88, 95% CI: 0.83-0.92) and total cholesterol was associated with increased risk only in iCOGS data (OR: 1.06, 95% CI: 1.01-1.12). In Egger regression models, only total cholesterol was associated with breast cancer risk (OR: 0.92, 95% CI: 0.85-1.00), although based on the Egger intercept, this instrumental variable suffered from directional pleiotropy. We also conducted weighted multivariable regression with mutual adjustment for other lipid traits.<sup>27,28</sup> Increasing HDL-C was associated with increased breast cancer risk in iCOGS data (OR: 1.16, 95% CI: 1.08-1.25), and higher triglycerides were associated with decreased breast cancer risk in OncoArray data (OR: 0.88, 95% CI: 0.81-0.95). Finally, we employed a weighted-median approach that assumes half of included variants are invalid.<sup>26</sup> Only HDL-C was associated with increased breast cancer risk after meta-analysis across our data sources (OR: 1.08, 95% CI: 1.02-1.14).

## DISCUSSION

In this large-scale Mendelian randomization study using 162 lipid-associated GWAS variants, we found that higher levels of genetically predicted HDL-C were associated with an increased risk of breast cancer. This finding was robust and consistent across a variety of analytic approaches. Genetically predicted triglyceride and total cholesterol levels were also associated with breast cancer risk in some analyses, but these findings were not consistent, and varied by data source and statistical adjustment. Genetically predicted LDL-C was not associated with breast cancer risk in any analyses. Traditional epidemiologic studies that have measured circulating lipids and evaluated breast cancer risk have had conflicting results, likely due to reverse causation, confounding, and selection bias. By using a Mendelian randomization approach, we aimed to overcome limitations inherent in traditional studies, and provide strong evidence supporting a possibly causal association between high HDL-C levels and increased breast cancer risk.

A recent study of serum lipids found that higher HDL-C was associated with increased breast cancer risk when serial measurements were assessed, but not when only one baseline measure was evaluated.<sup>17</sup> This contrasts with a meta-analysis of prospective studies that found modest inverse associations with breast cancer risk for both total cholesterol and HDL-C.<sup>15</sup> Given that circulating cholesterol levels are often decreased several years before cancer diagnosis, inverse associations for this trait could be attributable to bias from reverse causation. In addition, residual confounding from factors such as mammographic breast density or alcohol intake could also affect some reported associations.<sup>18</sup> Menopausal status and female steroid hormones also likely influence associations between circulating lipids and breast cancer risk.<sup>18</sup>



Plasma lipoproteins transport triglycerides and cholesterol between the liver and tissues. HDL-C is the smallest and most dense lipoprotein, and accounts for approximately 30% of total cholesterol, with levels ranging between 40-60 mg/dL. Higher HDL-C concentrations are associated with better cardiovascular health and lower coronary heart disease risk.<sup>10</sup> However, recent Mendelian randomization analyses have suggested that high HDL-C may not be causally related to reduced coronary heart disease risk.<sup>11,12</sup> Furthermore, pharmacologic interventions to increase HDL-C levels have not consistently translated to improved health outcomes,<sup>13,14</sup> and a consensus statement from the National Lipid Association concluded that HDL-C is not currently a therapeutic target.<sup>10</sup> Instead, measures of HDL functionality may be more important than absolute levels, as not all HDL-C functions the same way.<sup>10</sup> For example, oxidized HDL-C and HDL-C from patients with type 2 diabetes had greater capacity to promote proliferation, migration, and metastasis of breast cancer cells.<sup>30</sup> In addition to a major role in reverse cholesterol transport and anti-atherogenic effects, HDL-C also seems to have other functions including the potential to enhance proliferation of breast cancer cells.<sup>30,31</sup> These data provide possible biological mechanisms supporting the increased breast cancer risk seen with increasing levels of genetically predicted HDL-C in our study.

In the current study, associations for triglycerides and total cholesterol in relation to breast cancer risk were inconsistent. The total cholesterol wGS was associated with breast cancer risk only among iCOGS genotyped participants, and multivariate adjustment attenuated this association. Similarly, genetically predicted triglycerides were associated with reduced breast cancer risk only among OncoArray genotyped participants, and the exclusive variant instrument did not influence breast cancer risk. This suggests that some previously reported

associations may be due to residual confounding, and that additional evaluation to understand these discrepant findings may be warranted.

Strengths of this study include a very large sample size, strong instrumental variables for all four lipid traits (F-statistics >10),<sup>32</sup> and multiple analytic approaches to assess instrument validity. We included 162 variants reported by the Global Lipids Genetics Consortium, which account for approximately 13.7%, 14.6%, 11.7%, and 15.0% of the variance in HDL-C, LDL-C, triglycerides, and total cholesterol, respectively.<sup>20,21</sup> Only one variant was associated with breast cancer risk at a genome-wide significance level (rs1121980), and exclusion did not materially alter our results (data not shown). Furthermore, given the large number of variants used to construct our instruments, our wGSs are likely to be most strongly associated with lipids, and not as strongly associated with other traits. Given that pleiotropy remains a concern for Mendelian randomization analyses, we carefully evaluated this possibility using several analytic approaches<sup>26,27</sup> Associations from exclusive variant wGS, inverse variance weighted Mendelian randomization, and weighted-median regression analysis were consistent, showing associations between HDL-C and breast cancer risk. In addition, our results were also unaltered whether fixed-effect or random-effect meta-analysis was conducted (data not shown).

Limitations of our study may include that we did not have direct measurements of circulating lipid levels from our study population to further confirm the validity of our instrumental variables. However, in Mendelian randomization analyses, it is preferable to use externally-derived weights for constructing genetic scores rather than internally-derived weights from the same study population as the Mendelian randomization analysis.<sup>33</sup> We included external weights from a single large GWAS that was conducted predominantly among

Europeans,<sup>20,21</sup> and included only women of European descent in the current analysis. Recently, additional lipid trait genetic variants have been reported;<sup>34</sup> however, weights from this multi-ethnic GWAS would not be applicable to our study population. Additional limitations include incomplete information on all confounding factors, and we could not evaluate or adjust for all such possible covariates. However, when we adjusted for known breast cancer risk factors that were associated with our lipid trait wGSs, our results for HDL-C were unaltered. Finally, many variants included in our analysis were not directly genotyped. However, we used only imputed variants of high quality (iCOGS: mean  $r^2 = 0.82$ , range=0.35-0.99; OncoArray; mean  $r^2 = 0.98$ , range=0.86-0.99). Any misclassification of genetic variants would be expected to be non-differential with regard to our outcome, which would be more likely to attenuate rather than amplify an association.

In conclusion, our Mendelian randomization analysis of circulating lipids demonstrated that genetically predicted levels of increasing HDL-C are associated with increased breast cancer risk. Given the strong methodology used in this study, our results may help to clarify the inconsistencies observed across prior conventional observational studies, and support the hypothesis that circulating lipids may influence breast cancer risk.

## References

1. Hiatt RA, Friedman GD, Bawol RD, Ury HK. Breast cancer and serum cholesterol. *J Natl Cancer Inst.* 1982 Jun;**68**(6):885–889.
2. Törnberg SA, Holm LE, Carstensen JM, Eklund GA. Risks of cancer of the colon and rectum in relation to serum cholesterol and beta-lipoprotein. *N Engl J Med.* 1986 Dec 25;**315**(26):1629–1633.
3. Williams RR, Sorlie PD, Feinleib M, McNamara PM, Kannel WB, Dawber TR. Cancer incidence by levels of cholesterol. *JAMA.* 1981 Jan 16;**245**(3):247–252.
4. Schatzkin A, Hoover RN, Taylor PR, et al. Serum cholesterol and cancer in the NHANES I epidemiologic followup study. National Health and Nutrition Examination Survey. *Lancet.* 1987 Aug 8;**2**(8554):298–301.
5. Rose G, Shipley MJ. Plasma lipids and mortality: a source of error. *Lancet.* 1980 Mar 8;**1**(8167):523–526.
6. International Collaborative Group. Circulating cholesterol level and risk of death from cancer in men aged 40 to 69 years: Experience of an international collaborative group. *JAMA.* 1982 Dec 3;**248**(21):2853–2859.
7. Winawer SJ, Flehinger BJ, Buchalter J, Herbert E, Shike M. Declining serum cholesterol levels prior to diagnosis of colon cancer. A time-trend, case-control study. *JAMA.* 1990 Apr 18;**263**(15):2083–2085.
8. Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. The Whitehall Study. *JAMA.* 1992 Jan 1;**267**(1):70–76.
9. Iribarren C, Reed DM, Burchfiel CM, Dwyer JH. Serum total cholesterol and mortality. Confounding factors and risk modification in Japanese-American men. *JAMA.* 1995 Jun 28;**273**(24):1926–1932.
10. Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. *J Clin Lipidol.* 2013 Oct;**7**(5):484–525.
11. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet.* 2012 Aug 11;**380**(9841):572–580.
12. Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. *Eur Heart J.* 2015 Mar 1;**36**(9):539–550.

13. Boekholdt SM, Arsenault BJ, Hovingh GK, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. *Circulation*. 2013 Oct 1;**128**(14):1504–1512.
14. Kühnast S, Fiocco M, Hoorn JWA van der, Princen HMG, Wouter Jukema J. Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising. A systematic review and meta-analysis of relevant preclinical studies and clinical trials. *Eur J Pharmacol*. 2015 May 16;
15. Touvier M, Fassier P, His M, et al. Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies. *Br J Nutr*. 2015 Jul 15;1–11.
16. Borgquist S, Butt T, Almgren P, et al. Apo-lipoproteins, lipids and risk of cancer. *Int J Cancer*. 2016 Jan 25;
17. Martin LJ, Melnichouk O, Huszti E, et al. Serum lipids, lipoproteins, and risk of breast cancer: a nested case-control study using multiple time points. *J Natl Cancer Inst*. 2015 May;**107**(5).
18. Byers T, Goff D. Breast cancer, heart disease, and whispering ‘fire’ in a public theater. *J Natl Cancer Inst*. 2015 May;**107**(5).
19. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet*. 2014 Sep 15;**23**(R1):R89–98.
20. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*. 2010 Aug 5;**466**(7307):707–713.
21. Global Lipids Genetics Consortium, Willer CJ, Schmidt EM, et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet*. 2013 Nov;**45**(11):1274–1283.
22. Michailidou K, Lindström S, Dennis J, et al. Association analysis identifies 65 new breast cancer risk loci. *Nature*. 2017 Oct 23;
23. Michailidou K, Beesley J, Lindstrom S, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nat Genet*. 2015 Apr;**47**(4):373–380.
24. Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nat Genet*. 2013 Apr;**45**(4):353–361, 361e1–2.
25. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol*. 2013 Nov;**37**(7):658–665.

26. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015 Apr;**44**(2):512–525.
27. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol*. 2015 Feb 15;**181**(4):251–260.
28. Burgess S, Dudbridge F, Thompson SG. Re: ‘Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects’. *Am J Epidemiol*. 2015 Feb 15;**181**(4):290–291.
29. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol*. 2016 May;**40**(4):304–314.
30. Pan B, Ren H, He Y, et al. HDL of patients with type 2 diabetes mellitus elevates the capability of promoting breast cancer metastasis. *Clin Cancer Res*. 2012 Mar 1;**18**(5):1246–1256.
31. Rotheneder M, Kostner GM. Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines. *Int J Cancer*. 1989 May 15;**43**(5):875–879.
32. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. *Int J Epidemiol*. 2011 Jun;**40**(3):740–752.
33. Zhang B, Shu XO, Delahanty RJ, et al. Height and risk of breast cancer in women: evidence from prospective studies and Mendelian randomisation. *J Natl Cancer Inst*. 2015;
34. Hoffmann TJ, Theusch E, Haldar T, et al. A large electronic-health-record-based genome-wide study of serum lipids. *Nat Genet*. 2018 Mar 5;

**Author's Contributions:** WZ conceived and directed the study. NKK, RJD, and ABF conducted the statistical analysis. ABF, RJD, NKK, and WZ wrote the manuscript. DFE led the BCAC and COGS. KM, MKB, QW, JD, RLM, MKS, JS, PDPP, and GCT contributed significantly to the BCAC and COGS. All authors contributed to collection of the data and biological samples in the original studies, and data preparation for collaboration in BCAC. All authors reviewed the manuscript and approved its submission for publication.

**Potential Conflicts of Interests:** All authors declare that they have no financial or personal relationships with other people or organizations that could inappropriately influence this work.

**Role of the Funding Sources:** The study sponsors had no role in study design; in the collection, analysis, and interpretation of data; in the writing of this report; or in the decision to submit the paper for publication. The corresponding author confirms that he had full access to all the data included in the study and had final responsibility for the decision to submit this manuscript for publication.

## Funding

This work was supported by a National Cancer Institute at the National Institutes of Health research grant [R37CA070867] and endowment funds for the Ingram Professorship and Anne Potter Wilson Chair. N.K.K. was supported by a National Institutes of Health training grant [R25CA160056]. **BCAC** is funded by Cancer Research UK [C1287/A16563, C1287/A12014] and by the European Community's Seventh Framework Programme under grant agreement number 223175 [grant number HEALTH-F2-2009-223175] (COGS). Funding for the **iCOGS** infrastructure came from: the European Community's Seventh Framework Programme under grant agreement n° 223175 [HEALTH-F2-2009-223175] (COGS), Cancer Research UK [C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565], the National Institutes of Health [CA128978] and Post-Cancer GWAS initiative [1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative], the Department of Defense [W81XWH-10-1-0341], the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research [grant GPH-129344] and, the Ministère de l'Économie, Science et Innovation du Québec through Genome Québec and the PSRSIIRI-701 grant, and the Quebec Breast Cancer Foundation. The DRIVE Consortium was funded by U19 CA148065. The Australian Breast Cancer Family Study (**ABCFS**) was supported by the National Institutes of Health (USA) [UM1 CA164920]. The content of this manuscript does not necessarily reflect the views or policies of the National Institutes of Health or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Australia Fellow and M.C.S. is a NHMRC Senior Research Fellow. The **ABCS** study was supported by the Dutch Cancer Society [grants NKI 2007-3839; 2009 4363] and BBMRI-NL, which is a Research Infrastructure financed by the Dutch government [NWO 184.021.007]. The work of the **BBCC** was partly funded by ELAN-Fond of the University Hospital of Erlangen. The **BBCS** is funded by Cancer Research UK and Breakthrough Breast Cancer and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). Elinor J Sawyer (**BIGGS**) is supported by NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, United Kingdom; Ian Tomlinson is supported by the Oxford Biomedical Research Centre. The **BSUCH** study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the German Cancer Research Center (DKFZ). The **CECILE** study was funded by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de Sécurité Sanitaire (ANSES), Agence Nationale de la Recherche (ANR). The **CGPS** was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council and Herlev Hospital. The **CNIO-BCS** was



supported by the Spanish Network on Rare Diseases (CIBERER) and grants from the Asociación Española Contra el Cáncer and the Fondo de Investigación Sanitario [PI11/00923 and PI12/00070]. The Human Genotyping-CEGEN Unit (CNIO) is supported by the Instituto de Salud Carlos III. The **CTS** was initially supported by the California Breast Cancer Act of 1993 and the California Breast Cancer Research Fund [contract 97-10500] and is currently funded through the National Institutes of Health [R01 CA77398]. Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. HAC receives support from the Lon V Smith Foundation [LVS39420]. The **ESTHER** study was supported by a grant from the Baden Württemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). The **GC-HBOC** was supported by Deutsche Krebshilfe [107 352]. The **GENICA** was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the RuhrUniversity Bochum (IPA), as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus Bonn, Germany. **HEBCS** was supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, and the Sigrid Juselius Foundation. The **HMBCS** was supported by the Rudolf Bartling Foundation. Financial support for **KARBAC** was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V Jubilee foundation and Bert von Kantzows Foundation. The **KBCP** was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, the Academy of Finland and by the strategic funding of the University of Eastern Finland. **kConFab** is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. **LMBC** is supported by the 'Stichting tegen Kanker' [232-2008 and 196-2010]; Diether Lambrechts is supported by the FWO and the KULPFV/10/016-SymBioSysII and by a ERC consolidator grant. The **MARIE** study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I, 106332, 108253, 108419], the Hamburg Cancer Society, the German Cancer Research Center (DKFZ), and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. **MBCSG** is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects "5x1000"). The **MCBCS** was supported by National Institutes of Health grants [CA116167, CA176785, CA192393] a National Institutes of Health Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], the Breast Cancer Research Foundation and a generous gift from the David F. and Margaret T. Grohne Family Foundation. **MCCS** cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553 and 504711 and by infrastructure provided by Cancer Council Victoria. The **MEC** was

support by National Institutes of Health grants [CA63464, CA54281, CA098758 and CA132839]. The work of **MTLGEBCS** was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program [grant # CRN-87521] and the Ministry of Economic Development, Innovation and Export Trade [grant # PSR-SIIRI-701]. The **NBCS** was supported by grants from the Norwegian Research council, [155218/V40, 175240/S10 to A.L.B.D., FUGE-NFR 181600/V11 to V.N.K. and a Swizz Bridge Award to ALBD]. The **NBHS** was supported by National Institutes of Health [R01CA100374]; biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by National Institutes of Health (P30 CA68485). The **OBCS** was supported by research grants from the Finnish Cancer Foundation, the Academy of Finland [grant number 250083, 122715 and Center of Excellence grant number 251314], the Finnish Cancer Foundation, the Sigrid Juselius Foundation, the University of Oulu, the University of Oulu Support Foundation and the special Governmental EVO funds for Oulu University Hospital-based research activities. The **OFBCR** was supported by National Institutes of Health [UM1 CA164920]. The content of this manuscript does not necessarily reflect the views or policies of the National Institutes of Health or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. The **ORIGO** study was supported by the Dutch Cancer Society [RUL 1997-1505] and the Biobanking and Biomolecular Resources Research Infrastructure [BBMRI-NL CP16]. The **PBCS** was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The **pKARMA** study was supported by Märit and Hans Rausings Initiative Against Breast Cancer. The **RBCS** was funded by the Dutch Cancer Society [DDHK 2004-3124, DDHK 2009-4318]. The **SASBAC** study was supported by funding from the Agency for Science, Technology and Research of Singapore (A\*STAR), the US National Institute of Health and the Susan G. Komen Breast Cancer Foundation. The **SBCS** was supported by Sheffield Experimental Cancer Medicine Centre and the Breast Cancer Now Tissue Bank. **SEARCH** is funded by Cancer Research UK [C490/A10124, C490/A16561] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The University of Cambridge has received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. **SKKDKFZS** is supported by the DKFZ. The **SZBCS** was supported by Grant PBZ\_KBN\_122/P05/2004. The **TNBCC** was supported by: a Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], a grant from the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation, the Hellenic Cooperative Oncology Group research grant [HR R\_BG/04] and the Greek General Secretary for Research and Technology (GSRT) Program, Research Excellence II, the European Union (European Social Fund – ESF), and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - ARISTEIA. The **UKBGS** is funded by Breast Cancer Now and the Institute of Cancer Research (ICR), London. ICR acknowledges NHS funding to the NIHR Biomedical Research Centre.

## Acknowledgements

**BCAC** thanks all the individuals who took part in these studies and all the researchers, clinicians, technicians and administrative staff who have enabled this work to be carried out. This study would not have been possible without the contributions of the following: Per Hall (COGS); Douglas F. Easton, Paul Pharoah, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang (BCAC), Andrew Berchuck (OCAC), Rosalind A. Eeles, Douglas F. Easton, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Georgia Chenevix-Trench, Antonis Antoniou, Lesley McGuffog, Fergus Couch and Ken Offit (CIMBA), Joe Dennis, Alison M. Dunning, Andrew Lee, and Ed Dicks, Craig Luccarini and the staff of the Centre for Genetic Epidemiology Laboratory, Javier Benitez, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff of the McGill University and Génome Québec Innovation Centre, Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA laboratory, and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility. The **ABCFS** wishes to thank Maggie Angelakos, Judi Maskiell, and Gillian Dite. The **ABCS** would like to thank C Ellen van der Schoot, Femke Atsma, and the Sanquin Bloodbank. The **BBC** wishes to thank Matthias Rübner, Silke Landrith, Alexander Hein, Michael Schneider, and Sonja Oeser. The **BBCS** thanks Eileen Williams, Elaine Ryder-Mills, and Kara Sargus. The **BIGGS** wishes to thank Michael Kerin, Nicola Miller, Niall McInerney, and Gabrielle Colleran. The **BSUCH** would like to thank Peter Bugert and the Medical Faculty Mannheim. The **CECILE** study thanks Pierre Kerbrat, Patrick Arveux, Romuald Le Scodan, Yves Raoul, Pierre Laurent-Puig, and Claire Mulot. We thank the staff and participants of the Copenhagen General Population Study (**CGPS**). For the excellent technical assistance: Dorthe Uldall Andersen, Maria Birna Arnadottir, Anne Bank, Dorthe Kjeldgård Hansen. The Danish Breast Cancer Group (DBCG) is acknowledged for the tumor information. The Danish Cancer Biobank is acknowledged for providing infrastructure for the collection of blood samples for the cases. **CNIO-BCS** wishes to thank Guillermo Pita, Charo Alonso, Daniel Herrero, Nuria Álvarez, Pilar Zamora, Primitiva Menendez, and the Human Genotyping-CEGEN Unit (CNIO). The **CTS** Steering Committee includes Leslie Bernstein, Susan Neuhausen, James Lacey, Sophia Wang, Huiyan Ma, Yani Lu, and Jessica Clague DeHart at the Beckman Research Institute of City of Hope, Dennis Deapen, Rich Pinder, Eunjung Lee, and Fred Schumacher at the University of Southern California, Pam Horn-Ross, Peggy Reynolds, Christina Clarke Dur and David Nelson at the Cancer Prevention Institute of California, and Hoda Anton-Culver, Argyrios Ziogas, and Hannah Park at the University of California Irvine. The **ESTHER** study thanks Hartwig Ziegler, Sonja Wolf, Volker Hermann, Christa Stegmaier and Katja Butterbach. **GC-HBOC** thanks Heide Hellebrand, Stefanie Engert and GC-HBOC (Supported by Deutsche Krebshilfe). The **GENICA** network is acknowledged: [Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Germany; (HB, Wing-Yee Lo, Christina Justenhoven), Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany (YDK, Christian Baisch), Institute of Pathology, University of Bonn, Germany (Hans-Peter Fischer), Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ) Heidelberg, Germany (Ute Hamann), Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA),

Germany (Thomas Brüning, Beate Pesch, Sylvia Rabstein, Anne Lotz), Institute of Occupational Medicine and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Germany (Volker Harth)]. **HEBCS** thanks Kristiina Aittomäki and Taru A. Muranen. **HMBCS** thanks Natalia Antonenkova, Peter Hillemanns, Hans Christiansen and Johann H. Karstens. **KBCP** wishes to thank Eija Myöhänen and Helena Kemiläinen. We wish to thank Heather Thorne, Eveline Niedermayr, all the **kConFab** research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (which has received funding from the NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the National Institute of Health (USA)) for their contributions to this resource, and the many families who contribute to kConFab. **LMBC** thanks Gilian Peuteman, Dominiek Smeets, Thomas Van Brussel and Kathleen Corthouts. The **MARIE** study wishes to thank Dieter Flesch-Janys, Petra Seibold, Judith Heinz, Nadia Obi, Alina Vrieling, Sabine Behrens, Ursula Eilber, Muhabbet Celik, Til Olchers and Stefan Nickels. **MBCSG** wishes to thank Siranoush Manoukian, Bernard Peissel and Daniela Zaffaroni of the Fondazione IRCCS Istituto Nazionale dei Tumori (INT); Paolo Peterlongo of the FIRC Institute of Molecular Oncology (IFOM); Monica Barile and Irene Feroce of the Istituto Europeo di Oncologia (IEO) and Loris Bernard and the personnel of the Cogentech Cancer Genetic Test Laboratory. **MCBCS** would like to thank Emily Hallberg, Curtis Olswold, and Susan Slager. **MCCS** cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index. **MTLGEBCS** would like to thank Martine Tranchant (Cancer Genomics Laboratory, CHU de Québec Research Center), Marie-France Valois, Annie Turgeon and Lea Heguy (McGill University Health Center, Royal Victoria Hospital; McGill University) for DNA extraction, sample management and skillful technical assistance. J.S. is Chairholder of the Canada Research Chair in Oncogenetics. Silje Nord (**NBCS**) has a carrier grant from the Health Region South East (HSØ, grant nr 2014061). The **NBHS** wishes to thank study participants and research staff for their contributions and commitment to the study. The **OBCS** wishes to thank Arja Jukkola-Vuorinen, Mervi Grip, Saila Kauppila, Meeri Otsukka and Kari Mononen. The **OFBCR** thanks Teresa Selander and Nayana Weerasooriya. **ORIGO** thanks E. Krol-Warmerdam and J. Blom for patient accrual, administering questionnaires, and managing clinical information. The LUMC survival data were retrieved from the Leiden hospital-based cancer registry system (ONCDOC) with the help of Dr. J. Molenaar. **PBCS** wishes to thank Louise Brinton, Mark Sherman, Neonila Szeszenia-Dabrowska, Beata Peplonska, Witold Zatonski, Pei Chao, and Michael Stagner. The **pKARMA** study wishes to thank the Swedish Medical Research Counsel. The **RBCS** thanks Petra Bos, Jannet Blom, Ellen Crepin, Elisabeth Huijskens, Annette Heemskerk, and the Erasmus MC Family Cancer Clinic. The **SASBAC** study wishes to thank the Swedish Medical Research Counsel. The **SBCS** thanks Sue Higham, Helen Cramp, Ian Brock, Sabapathy Balasubramanian and Dan Connley. We wish to thank the **SEARCH** and EPIC teams. We thank all study participants, clinicians, family doctors, researchers and technicians for their contributions and commitment to the **SKKDKFZS** study. **UKBGS** thanks Breast Cancer Now and the Institute of Cancer Research for support and funding of the Breakthrough Generations Study, and the study participants, study staff, and the doctors, nurses and other health care providers and health information sources who have contributed to the study. **WHI** program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C,

HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: <http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Long%20List.pdf>. We acknowledge NHS funding to the Royal Marsden/ICR NIHR Biomedical Research Centre. Finally, the authors wish to acknowledge Samantha P. Stansel, Kim Kreth, and Lisa Long for assistance with preparing and submitting this manuscript, and numerous colleagues in the Vanderbilt Division of Epidemiology, for their many discussions and helpful insight into breast cancer epidemiology and Mendelian randomization analysis.

**Table 1.** Associations between one standard deviation (SD) increase in genetically predicted lipid traits and breast cancer risk using individual-level data in the Breast Cancer Association Consortium (BCAC) for original and amended lipid-specific instruments and for different covariate adjustment

Variants used in instrument	Cases	Controls	High density lipoprotein (HDL-C) wGS			Low density lipoprotein (LDL-C) wGS			Triglycerides (TG) wGS			Total cholesterol (TC) wGS		
			OR <sup>a</sup>	95% CI	P	OR <sup>a</sup>	95% CI	P	OR <sup>a</sup>	95% CI	P	OR <sup>a</sup>	95% CI	P
<b>All Variants<sup>b</sup></b>														
No adjustment	101 424	80 253	1.10	1.04-1.17	2.1x10 <sup>-3</sup>	1.00	0.97-1.03	0.86	1.01	0.97-1.05	0.57	1.08	1.04-1.11	5.7x10 <sup>-5</sup>
Adjusted <sup>d</sup>	101 424	80 253	1.12	1.08-1.16	1.7x10 <sup>-9</sup>	1.00	0.96-1.04	0.88	0.93	0.85-1.01	7.5x10 <sup>-2</sup>	1.05	0.99-1.11	0.11
<b>Exclusive Variants<sup>c</sup></b>														
No adjustment	101 424	80 253	1.12	0.98-1.28	9.2x10 <sup>-2</sup>	1.01	0.96-1.05	0.78	1.16	1.08-1.25	1.3x10 <sup>-4</sup>	NE	NE	NE
Adjusted <sup>d</sup>	101 424	80 253	1.14	1.07-1.22	9.9x10 <sup>-5</sup>	1.00	0.95-1.05	0.95	1.00	0.86-1.16	0.98	NE	NE	NE

<sup>a</sup> Random-effects meta-analysis estimate and 95% CI summarizing the associations reported in iCOGS and OncoArray BCAC datasets for the association between lipid-specific wGSs and breast cancer risk.

<sup>b</sup> Number of variants included in weighted-genetic score (wGS) per lipid trait: HDL-C = 74, LDL-C = 57, TG = 43, and TC = 74.

<sup>c</sup> Number of variants included in amended wGS per lipid trait: HDL-C = 54, LDL-C = 42, TG = 20; NE not evaluated.

<sup>d</sup> Models adjusted for age, study (iCOGS) or country (OncoArray), and top 6 (iCOGS) or top 10 (OncoArray) principal components for European ancestry.

**Table 2.** Stratified analyses for the association between one standard deviation (SD) increase in genetically predicted lipid traits and breast cancer risk using individual-level iCOGS and OncoArray data summarized using random-effects meta-analysis in the Breast Cancer Association Consortium (BCAC)

Subgroup	Cases	Controls	High density lipoprotein (HDL-C) wGS <sup>a</sup>			Low density lipoprotein (LDL-C) wGS <sup>a</sup>			Triglycerides (TG) wGS <sup>a</sup>			Total cholesterol (TC) wGS <sup>a</sup>		
			OR <sup>b</sup>	95% CI <sup>b</sup>	P	OR <sup>b</sup>	95% CI <sup>b</sup>	P	OR <sup>b</sup>	95% CI <sup>b</sup>	P	OR <sup>b</sup>	95% CI <sup>b</sup>	P
<b>Menopausal status</b>														
Premenopausal	20 782	17 902	1.14	0.96-1.35	0.13	1.00	0.92-1.08	0.89	0.90	0.75-1.08	0.24	1.08	1.00-1.17	0.04
Postmenopausal	43 787	38 847	1.11	1.05-1.17	3.2x10 <sup>-4</sup>	0.99	0.94-1.05	0.80	0.93	0.88-0.99	0.03	1.00	0.95-1.05	0.96
<i>Test for Interaction<sup>c</sup></i>			<i>P<sub>iCOGS</sub> = 0.04, P<sub>Onco</sub> = 0.23</i>			<i>P<sub>iCOGS</sub> = 0.31, P<sub>Onco</sub> = 0.41</i>			<i>P<sub>iCOGS</sub> = 0.41, P<sub>Onco</sub> = 0.05</i>			<i>P<sub>iCOGS</sub> = 0.13, P<sub>Onco</sub> = 0.37</i>		
<b>Age</b>														
< 50 years	24 572	22 944	1.17	1.01-1.34	3.4x10 <sup>-2</sup>	0.96	0.90-1.03	0.30	0.90	0.78-1.05	0.17	1.05	0.98-1.12	0.20
≥ 50 years	71 098	51 700	1.11	1.06-1.16	2.3x10 <sup>-6</sup>	1.01	0.97-1.05	0.65	0.93	0.89-0.98	6.7x10 <sup>-3</sup>	1.04	0.99-1.08	0.12
<i>Test for Interaction<sup>c</sup></i>			<i>P<sub>iCOGS</sub> = 0.07, P<sub>Onco</sub> = 0.74</i>			<i>P<sub>iCOGS</sub> = 0.14, P<sub>Onco</sub> = 0.68</i>			<i>P<sub>iCOGS</sub> = 0.78, P<sub>Onco</sub> = 0.13</i>			<i>P<sub>iCOGS</sub> = 0.71, P<sub>Onco</sub> = 0.99</i>		
<b>Body mass index (BMI)</b>														
BMI < 30 kg/m <sup>2</sup>	51 114	41 713	1.14	1.08-1.20	1.0x10 <sup>-6</sup>	0.99	0.94-1.04	0.70	0.90	0.83-0.98	1.7x10 <sup>-2</sup>	1.04	0.97-1.12	0.29
BMI ≥ 30 kg/m <sup>2</sup>	12 200	9 507	1.06	0.95-1.18	0.31	0.95	0.85-1.05	0.31	1.07	0.95-1.21	0.29	0.96	0.87-1.06	0.41
<i>Test for Interaction<sup>c</sup></i>			<i>P<sub>iCOGS</sub> = 0.67, P<sub>Onco</sub> = 0.24</i>			<i>P<sub>iCOGS</sub> = 0.16, P<sub>Onco</sub> = 0.99</i>			<i>P<sub>iCOGS</sub> = 0.22, P<sub>Onco</sub> = 1.9x10<sup>-2</sup></i>			<i>P<sub>iCOGS</sub> = 0.10, P<sub>Onco</sub> = 0.68</i>		
<b>Estrogen receptor (ER) status</b>														
ER- breast cancer	43 039	80 253	1.10	1.03-1.18	7.0x10 <sup>-3</sup>	0.99	0.93-1.05	0.73	0.94	0.87-1.01	8.3x10 <sup>-2</sup>	1.06	0.93-1.21	0.36
ER+ breast cancer	61 140	80 253	1.11	1.07-1.16	8.6x10 <sup>-8</sup>	0.99	0.95-1.03	0.63	0.91	0.85-0.98	1.4x10 <sup>-2</sup>	1.03	0.99-1.07	0.17
<i>Test for Heterogeneity<sup>c</sup></i>			<i>P<sub>iCOGS</sub> = 0.95, P<sub>Onco</sub> = 0.52</i>			<i>P<sub>iCOGS</sub> = 0.50, P<sub>Onco</sub> = 0.61</i>			<i>P<sub>iCOGS</sub> = 0.97, P<sub>Onco</sub> = 0.26</i>			<i>P<sub>iCOGS</sub> = 0.16, P<sub>Onco</sub> = 0.69</i>		

<sup>a</sup> Number of variants included in lipid-specific weighted-genetic score (wGS): HDL-C = 74, LDL-C = 57, TG = 43, and TC = 74.

<sup>b</sup> Odds Ratios (OR) and 95% Confidence Intervals (CI) represent results from random-effects meta-analysis summarizing the associations from iCOGS and OncoArray datasets for 1 SD increase in wGS in relation to breast cancer risk among stratified groups. Polytomous regression was employed to estimate risk for ER+ and ER- breast cancer in the iCOGS and OncoArray datasets. All models were adjusted for age, BCAC study site (iCOGS) or study country (OncoArray), and either top 6 (iCOGS) or top 10 principal components for European ancestry (OncoArray).

<sup>c</sup> Interactions were assessed on a multiplicative scale using the likelihood ratio test (LRT) for nested models. Differences in stratum-specific ORs and 95% CIs for tumor subtype were assessed using a test for heterogeneity.

**Supplementary Table 1.** Summary statistics for associations between 162 lipid trait variants from the Global Lipids Genetics Consortium and breast cancer risk in the Breast Cancer Association Consortium (BCAC)

N	Varia	C	Hg38 Locati	Global Lipids Genetics Consortium *												Breast Cancer Association Consortium							
				HDL-C			LDL-C			TG			TC			iCOGS <sup>b</sup>			OncoArray				
				E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	Info Score <sup>c</sup>	$\beta$	P	Info Score <sup>c</sup>	
	rs1077		23439		0-0		0-0		0-0		0-0		0-0		0-0		0-0	T/					
1	rs1202	1		T/		8-3E-04	T/		1-0E-04	T/		1-3E-03	T/		6-4E-09	T/		0-010	5-1E-01	1-000	-0-011	4-2E-01	1-000
			25449		0-0		0-0		0-0		0-0		0-0		0-0		0-0	T/					
2	rs1274	1		T/		4-6E-01	T/		1-2E-10	T/		2-8E-02	T/		4-1E-11	T/		-0-023	4-1E-02	0-951	-0-007	4-5E-01	0-998
			26811		0-0		0-0		0-0		0-0		0-0		0-0		0-0	T/					
3	rs4660	1		C/		9-7E-16	T/		3-2E-12	T/		1-1E-09	T/		2-9E-06	G/		0-018	4-3E-01	0-732	0-032	5-4E-02	0-989
			39562		0-0		0-0		0-0		0-0		0-0		0-0		0-0	G/					
4	rs2479	1		A/		4-0E-10	G/		4-3E-03	G/		2-3E-06	G/		3-9E-02	A/		0-006	7-3E-01	0-578	0-006	5-8E-01	0-993
			55038		0-0		0-0		0-0		0-0		0-0		0-0		0-0	A/					
5	rs2131	1		A/		3-3E-01			1-9E-28	G/		9-2E-03			3-8E-24			-0-008	5-7E-01	0-699	-0-010	3-0E-01	1-000
			62560		0-0		0-0		0-0		0-0		0-0		0-0		0-0	T/					
6	rs7515	1		T/		2-8E-03	T/		1-6E-17	T/		8-8E-43	T/		2-7E-40	A/		-0-008	5-0E-01	1-000	0-007	4-9E-01	1-000
			92543		0-0		0-0		0-0		0-0		0-0		0-0		0-0	A/					
7		1		C/		9-8E-01	A/		1-5E-07	A/		1-8E-01	A/		2-8E-08			0-005	6-8E-01	0-996	0-010	3-9E-01	0-994
			10927		0-0		0-1		0-1		0-0		0-1		0-1		0-1	T/					
8	rs6293	1		G/		6-2E-08	T/		9-7E-171	T/		6-2E-02	T/		5-8E-131	G/		-0-015	2-4E-01	1-000	0-017	1-1E-01	1-000
			15098		0-0		0-0		0-0		0-0		0-0		0-0		0-0	G/					
9	rs2677	1		G/		3-6E-03	A/		5-3E-09	A/		6-2E-01	A/		3-8E-05			0-020	1-7E-01	1-000	0-013	3-0E-01	1-000
			15673		0-0		0-0		0-0		0-0		0-0		0-0		0-0	G/					
1		1		G		1-8E-08	T/		3-4E-01	T/		5-6E-04	G/		6-6E-01	A/		0-005	6-4E-01	0-975	0-000	1-0E+00	0-989
			17854		0-0		0-0		0-0		0-0		0-0		0-0		0-0	A/					
1	rs4650	1		G		0-0	A/		0-0	A/		0-0	G/		0-0		0-0						
						6-7E-09			3-4E-01			4-0E-01			3-5E-01			-0-006	5-8E-01	0-875	0-012	1-7E-01	1-000
1	rs1689	1		A/		0-0	G/		0-0	G/		0-0	A/		0-0		0-0	G/					
			18219		0-0		0-0		0-0		0-0		0-0		0-0		0-0						
1		1				3-2E-10			1-4E-01			1-0E-01			2-5E-01			0-016	2-5E-01	0-669	0-009	3-3E-01	0-990



N	Varia	C	Hg38 Locati	Global Lipids Genetics Consortium <sup>a</sup>												Breast Cancer Association Consortium											
				HDL-C			LDL-C			TG			TC			iCOGS <sup>b</sup>			OncoArray		Info Score <sup>c</sup>						
				E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	$\beta$	P	Info Score <sup>c</sup>						
			22080																	T/							
1	rs2642	1	23015	T/	0-0		T/	0-0		C/	0-0		T/	0-0						A/	-0-015	2-4E-01	0-829	-0-015	1-4E-01	0-955	
	rs4846	1	23472	A/	0-0		G/	0-0			0-0		A/	0-0													
	rs5142	1	21002	T/	0-0		T/	0-0		T/	0-0		T/	0-0							T/	0-004	8-2E-01	0-455	0-003	7-3E-01	1-000
	rs1042	2	21041	C/	0-0		T/	0-0		T/	0-0		T/	0-0							T/	-0-009	4-8E-01	0-676	0-006	4-8E-01	1-000
	rs1367	2	27508	G/	0-0		A/	0-1		A/	0-0		A/	0-1							A/	0-012	3-8E-01	1-000	-0-003	8-0E-01	1-000
	rs1260	2	43845	C/	0-0		T/	0-0		T/	0-1		T/	0-0							C/	0-015	1-8E-01	1-000	0-001	9-0E-01	1-000
	rs4299	2	62922	T/	0-0		G	0-0		G/	0-0		G	0-0							T/	-0-002	8-7E-01	1-000	0-023	1-4E-02	0-969
	rs2710	2	11807	G/	0-0		A/	0-0		A/	0-0		A/	0-0							A/	0-023	1-1E-01	0-693	0-005	6-1E-01	1-000
	rs1049	2	12055	A/	0-0		G	0-0		A/	0-0		G	0-0							A/	-0-008	5-0E-01	1-000	0-002	8-6E-01	1-000
	rs2030	2	13508	C/	0-0		T/	0-0		T/	0-0		T/	0-0							T/	0-024	2-4E-01	1-000	0-008	6-3E-01	1-000
	rs7570	2	16465	A/	0-0		A/	0-0		A/	0-0		A/	0-0							A/	0-015	2-2E-01	0-801	-0-001	8-9E-01	1-000
	rs1019	2	16468	C/	0-0		T/	0-0		T/	0-0		T/	0-0							C/	0-004	7-7E-01	0-840	-0-009	4-1E-01	0-870
	rs1232	2	16468	C/	0-0		T/	0-0		T/	0-0		T/	0-0							C/	-0-025	2-3E-02	1-000	-0-002	8-1E-01	1-000
		2		C/	0-0		T/	0-0		T/	0-0		T/	0-0							C/	0-012	4-7E-01	0-997	0-004	7-4E-01	0-992

N	Varia	C	Hg38 Locati	Global Lipids Genetics Consortium <sup>a</sup>												Breast Cancer Association Consortium						
				HDL-C			LDL-C			TG			TC			iCOGS <sup>b</sup>			OncoArray			
				E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	Info Score <sup>c</sup>	$\beta$	P	Info Score <sup>c</sup>
			16897																			
2	rs2287			G/	0-0		G/	0-0		A/	0-0		G	0-0								
		2	20266			2-0E-03					9-2E-01			<b>4-1E-12</b>		G/	0-023	9-9E-02	0-606	-0-008	3-7E-01	0-996
2	rs1169			A/	0-0		G/	0-0		G/	0-0		G	0-0								
		2	21067			7-7E-01					2-5E-05			<b>2-0E-09</b>		A/	0-009	4-7E-01	1-000	-0-006	5-5E-01	1-000
2	rs1047			C/	<b>0-0</b>		A/	0-0		C/	0-0		C/	0-0								
		2	21543			<b>8-7E-10</b>					8-6E-01		C/	1-8E-01		C/	0-032	1-9E-02	0-743	0-004	6-6E-01	1-000
2	rs1250			T/	0-0		C/	<b>0-0</b>		C/	0-0		C/	0-0								
		2	22623			4-0E-01					1-4E-02		C/	2-4E-07		T/	-0-008	5-4E-01	0-987	0-003	7-9E-01	0-979
3	rs2972			G	<b>0-0</b>		T/	0-0		T/	<b>0-0</b>		T/	0-0								
		2	23377			<b>2-8E-09</b>					7-2E-02			<b>2-5E-08</b>		T/	0-005	6-7E-01	0-967	-0-002	8-7E-01	0-996
3	rs1156			T/	0-0		T/	<b>0-0</b>		T/	0-0		T/	<b>0-0</b>								
		2	11358			3-6E-01					8-3E-02			<b>1-3E-09</b>		T/	0-014	4-2E-01	1-000	0-022	1-3E-01	1-000
3	rs2606			C/	<b>0-0</b>		T/	0-0		T/	0-0		C/	0-0								
		3	12587			<b>4-8E-08</b>					9-1E-01			1-2E-01		C/	-0-015	1-8E-01	0-997	0-019	4-3E-02	0-997
3	rs2290			G/	0-0		G/	0-0		G/	0-0		G	<b>0-0</b>								
		3	32491			4-4E-01					1-2E-06			<b>4-2E-09</b>		T/	0-000	9-9E-01	0-993	-0-005	6-7E-01	1-000
3	rs7640			T/	0-0		C/	<b>0-0</b>		C/	0-0		C/	<b>0-0</b>								
		3	47019			7-2E-01					5-5E-03			<b>1-7E-08</b>		A/	0-014	6-0E-01	0-626	0-008	6-2E-01	0-964
3	rs2290			G	<b>0-0</b>		A/	0-0		A/	0-0		G/	0-0								
		3	50091			<b>3-7E-09</b>					7-9E-01			1-1E-01		T/	0-002	8-8E-01	1-000	-0-009	4-7E-01	0-959
3	rs2013			T/	<b>0-0</b>		T/	0-0		C/	0-0		T/	0-0								
		3	52498			<b>8-9E-12</b>					9-7E-01			2-1E-02		G/	-0-001	9-0E-01	1-000	-0-023	9-9E-03	1-000
3	rs1332			A/	<b>0-0</b>		G/	0-0		G/	0-0		G/	0-0								
		3	58395			<b>9-0E-11</b>					2-7E-01			6-3E-01		A/	-0-021	1-6E-01	0-864	0-001	9-6E-01	1-000
3	rs1331			G/	0-0		G/	0-0		A/	0-0		G	<b>0-0</b>								
		3	11984			1-8E-02					4-7E-07			<b>3-5E-08</b>		C/	-0-017	3-7E-01	0-997	-0-003	8-6E-01	0-999
3	rs6805			T/	<b>0-0</b>		T/	0-0		C/	0-0		T/	0-0								
		3	11984			<b>1-3E-08</b>					1-9E-03			1-2E-06			-0-004	7-0E-01	0-999	-0-004	6-6E-01	1-000

N	Varia	C	Hg38 Locati	Global Lipids Genetics Consortium <sup>a</sup>												Breast Cancer Association Consortium								
				HDL-C			LDL-C			TG			TC			iCOGS <sup>b</sup>			OncoArray					
				E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	Info Score <sup>c</sup>	E/	$\beta$	P	Info Score <sup>c</sup>	
	rs1740		13244															T/						
4		3		G	0-0		G	0-0		G/	0-0		G/	0-0										
			13620			5-0E-09			1-8E-09		G/	2-2E-02		G/	1-4E-07			T/	-0-033	6-0E-02	0-829	-0-006	6-4E-01	0-983
4	rs6450			G/	0-0		T/	0-0		T/	0-0		T/	0-0										
		3				3-3E-06			2-2E-01			2-5E-08			3-5E-01			G/	-0-004	7-4E-01	0-991	-0-008	4-8E-01	0-998
4	rs6831		34714	A/	0-0		G	0-0		G	0-0		G	0-0				G/						
		4				3-0E-03			2-0E-08			1-6E-12			1-0E-10			G/	-0-023	5-5E-02	0-823	-0-004	6-4E-01	0-976
4	rs1001		26061	A/	0-0		G/	0-0		G/	0-0		G/	0-0										
		4				4-9E-08			3-2E-04			2-3E-06			1-2E-02			T/	0-026	1-2E-01	0-752	-0-010	4-1E-01	0-990
4	rs4421		87109	G/	0-0		T/	0-0		T/	0-0		T/	0-0										
		4				2-7E-07			9-8E-04			8-7E-12			4-0E-04			A/	0-017	1-3E-01	1-000	0-025	7-3E-03	0-994
4	rs3822		88820	G	0-0		A/	0-0		A/	0-0		A/	0-0										
		4				4-1E-12			3-7E-02			5-7E-07			5-2E-01			G/	0-001	9-6E-01	0-945	-0-004	6-3E-01	0-987
4	rs2602		99093	A/	0-0		G/	0-0		G/	0-0		A/	0-0										
		4				5-0E-08			8-3E-01			2-1E-02			6-6E-01			T/	0-002	8-5E-01	0-812	0-014	1-1E-01	1-000
4	rs1310		10226	C/	0-0		C/	0-0		T/	0-0		C/	0-0										
		4				7-2E-11			1-2E-01			1-5E-02			2-8E-03			A/	0-010	6-9E-01	0-744	-0-001	9-7E-01	1-000
4	rs6450		54002	G	0-0		A/	0-0		A/	0-0		A/	0-0										
		5				5-0E-08			9-1E-02			1-7E-05			5-6E-02			T/	0-028	2-5E-02	0-992	0-007	5-2E-01	1-000
4	rs9686		56565	C/	0-0		T/	0-0		T/	0-0		T/	0-0										
		5				7-5E-07			7-2E-03			1-3E-10			6-2E-03			C/	-0-019	2-4E-01	0-786	-0-019	9-9E-02	0-993
5	rs1291		75360	C/	0-0		C/	0-0		C/	0-0		C/	0-0										
		5				1-4E-01			5-1E-45			3-0E-01			8-8E-47			A/	0-008	4-9E-01	0-994	0-011	2-1E-01	1-000
5	rs4530		12351	A/	0-0		A/	0-0		A/	0-0		A/	0-0										
		5				9-3E-01			3-6E-12			7-4E-01			1-7E-09			C/	0-004	7-0E-01	1-000	0-002	8-1E-01	1-000
5	rs6882		15696	T/	0-0		C/	0-0		C/	0-0		C/	0-0										
		5				8-9E-01			1-9E-22			1-0E-10			7-5E-28			T/	0-017	2-2E-01	0-648	-0-014	1-4E-01	1-000
5	rs3757		16127	T/	0-0		C/	0-0		C/	0-0		C/	0-0										
		6				3-9E-01			1-2E-11			2-1E-01			2-8E-09									

N	Varia	C	Hg38 Locati	Global Lipids Genetics Consortium <sup>a</sup>												Breast Cancer Association Consortium					
				HDL-C			LDL-C			TG			TC			iCOGS <sup>b</sup>			OncoArray		
				E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	Info Score <sup>c</sup>	$\beta$	P
	rs1800		26092				<b>G</b>	<b>0-0</b>				<b>G</b>	<b>0-0</b>		A/						
5		6		G/	0-0	1-8E-01		<b>6-1E-10</b>	A/	0-0	7-5E-01		<b>2-5E-08</b>	T/	-0-024	3-2E-01	0-864	0-011	5-8E-01	1-000	
	rs2814		34578				C/	0-0	C/	0-0		T/	0-0	C/	0-0						
5		6		C/	0-0	1-3E-06		4-7E-07	T/	0-0	7-3E-01		<b>4-7E-11</b>	A/	-0-007	6-9E-01	0-835	-0-012	4-0E-01	1-000	
	rs2814		34585		<b>G</b>	<b>0-0</b>		0-0		0-0			0-0								
5		6		<b>G</b>	<b>0-0</b>	<b>3-8E-09</b>	G/	6-8E-05	A/	0-0	3-5E-01	G/	8-9E-08	A/	0-004	7-8E-01	1-000	-0-017	1-7E-01	0-999	
	rs2758		39283				G/	0-0	A/	0-0		A/	0-0	A/	0-0						
5		6		G/	0-0	7-3E-01		1-8E-07	A/	0-0	4-9E-02		<b>3-0E-08</b>	A/	0-011	3-4E-01	0-992	0-005	5-9E-01	0-997	
	rs9985		43790		<b>0-0</b>	<b>0-0</b>		0-0		<b>0-0</b>			0-0								
5		6		C/	<b>0-0</b>	<b>2-3E-11</b>	A/	9-4E-01	A/	<b>0-0</b>	<b>3-4E-15</b>	A/	5-3E-01	A/	-0-024	3-7E-02	0-868	-0-025	6-5E-03	1-000	
	rs9488		11599											T/							
5		6		A/	0-0	2-5E-01	<b>A/</b>	<b>0-0</b>	A/	0-0	1-9E-04	<b>A/</b>	<b>1-7E-10</b>	T/	0-004	7-7E-01	0-831	-0-009	3-5E-01	0-971	
	rs1936		12711		<b>0-0</b>	<b>0-0</b>		0-0		<b>0-0</b>			0-0								
6		6		C/	<b>0-0</b>	<b>3-1E-10</b>	T/	2-0E-01	T/	<b>0-0</b>	<b>3-8E-07</b>	T/	9-8E-01	C/	-0-016	1-9E-01	0-830	-0-017	5-3E-02	1-000	
	rs9376		13509																		
6		6		T/	0-0	2-9E-04	T/	0-0	T/	0-0	3-4E-01	T/	<b>2-6E-09</b>	T/	0-011	5-0E-01	0-596	0-005	6-6E-01	0-980	
	rs6050		13950		<b>0-0</b>	<b>0-0</b>		0-0		0-0			0-0								
6		6		T/	<b>0-0</b>	<b>2-6E-08</b>	C/	2-1E-02	C/	0-0	3-2E-06	C/	1-7E-01	C/	-0-012	2-5E-01	0-999	0-006	5-0E-01	0-993	
	rs1564		16015																		
6		6		T/	0-0	6-9E-02	<b>C/</b>	<b>0-0</b>	C/	0-0	2-4E-02	<b>C/</b>	<b>9-7E-17</b>	C/	-0-001	9-4E-01	1-000	-0-016	2-0E-01	1-000	
	rs1084		16066		<b>0-0</b>	<b>0-0</b>		0-0		0-0			0-0	A/							
6		6		<b>A/</b>	<b>0-0</b>	<b>3-0E-08</b>	G/	5-5E-01	A/	0-0	1-2E-02	G/	5-9E-02	G/	-0-044	2-3E-03	1-000	-0-023	5-9E-02	1-000	
	rs1997		10441									<b>G</b>	<b>0-0</b>								
6		7		G/	0-0	2-3E-07	G/	0-0	G/	0-0	2-7E-01	<b>G</b>	<b>0-0</b>	G/	0-023	1-3E-01	1-000	-0-014	2-5E-01	0-998	
	rs7024		64096		<b>G</b>	<b>0-0</b>		0-0		0-0			0-0	G/	0-023	1-3E-01	1-000	-0-014	2-5E-01	0-998	
6		7		<b>G</b>	<b>0-0</b>	<b>6-5E-12</b>	G/	7-9E-01	A/	0-0	4-8E-01	G/	2-9E-04	G/	-0-006	6-8E-01	0-600	0-011	2-2E-01	0-991	
	rs4142		17879		<b>G</b>	<b>0-0</b>		0-0		0-0			0-0	T/							
6		7		<b>G</b>	<b>0-0</b>	<b>9-4E-12</b>	G/	9-0E-02	T/	0-0	8-8E-03	G/	1-2E-05	G/	-0-032	1-1E-02	0-765	0-000	9-7E-01	0-994	
	rs1267		21567					<b>0-0</b>		0-0			<b>0-0</b>	C/							
6		7		T/	0-0	9-1E-01	<b>C/</b>	<b>6-9E-10</b>	C/	0-0	3-0E-02	<b>C/</b>	<b>9-2E-10</b>	C/	-0-006	6-7E-01	0-760	0-015	1-6E-01	0-995	

N	Varia	C	Hg38 Locati	Global Lipids Genetics Consortium <sup>a</sup>									Breast Cancer Association Consortium										
				HDL-C			LDL-C			TG			TC			iCOGS <sup>b</sup>			OncoArray				
				E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	Info Score <sup>c</sup>	E/	$\beta$	P	Info Score <sup>c</sup>
6	rs4722	7	25952	C/	0-0		C/	0-0		T/	0-0		C/	0-0		C/							
7	rs2072	7	44539		2-5E-02			<b>3-9E-14</b>			<b>1-6E-09</b>			<b>7-0E-09</b>		C/	0-021	2-1E-01	0-795	0-028	2-9E-02	0-894	
7	rs4917	7	50266	G/	0-0		C/	0-0		C/	0-0		C/	0-0		G/	0-033	5-1E-02	0-558	0-005	6-5E-01	1-000	
7	rs1323	7	72664	<b>G</b>	<b>0-0</b>		G/	0-0		T/	0-0		G/	0-0		T/	-0-008	6-4E-01	0-408	0-018	6-8E-02	1-000	
7	rs1714	7	73568	T/	0-0		C/	0-0		C/	0-0		C/	0-0		T/	0-056	1-6E-01	0-630	0-000	1-0E+00	0-859	
7	rs3885	7	11671	<b>T/</b>	<b>0-0</b>		T/	0-0		C/	0-1		C/	0-0		G/	0-077	4-3E-03	0-517	0-019	1-7E-01	1-000	
7	rs4731	7	13074	G/	0-0		A/	0-0		A/	0-0		A/	0-0		T/	0-006	6-1E-01	0-937	-0-002	8-7E-01	1-000	
7	rs1717	7	15083	T/	0-0		C/	0-0		C/	0-0		C/	0-0		C/	0-004	7-6E-01	0-570	0-026	3-6E-03	0-995	
7	rs9987	7	10826	<b>T/</b>	<b>0-0</b>		C/	0-0		C/	0-0		T/	0-0		G/	-0-029	1-1E-01	1-000	-0-046	2-7E-03	0-998	
7	rs1177	8	93258	<b>G</b>	<b>0-0</b>		<b>G</b>	<b>0-0</b>		A/	0-0		<b>G</b>	<b>0-0</b>		C/	0-028	1-4E-01	0-988	0-038	2-5E-02	0-994	
7	rs1495	8	18415	G/	0-0		G/	0-0		C/	0-0		G/	0-0		A/	0-009	4-2E-01	0-976	-0-007	4-8E-01	0-998	
7	rs1267	8	19986	A/	0-0		G/	0-0		<b>G</b>	<b>0-0</b>		<b>G</b>	<b>0-0</b>		G/	-0-024	6-0E-02	1-000	-0-010	3-6E-01	1-000	
8	rs1010	8	54509	<b>G</b>	<b>0-1</b>		A/	0-0		A/	0-1		A/	0-0		A/	0-015	3-9E-01	0-987	0-004	7-9E-01	1-000	
8		8		G/	0-0		A/	0-0		A/	0-0		A/	0-0			0-018	1-8E-01	0-973	0-000	9-8E-01	0-999	
					8-0E-01			<b>3-7E-11</b>			6-9E-03			<b>4-6E-11</b>									

N	Varia	C	Hg38 Locati	Global Lipids Genetics Consortium <sup>a</sup>												Breast Cancer Association Consortium						
				HDL-C			LDL-C			TG			TC			iCOGS <sup>b</sup>			OncoArray			
				E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	Info Score <sup>c</sup>	$\beta$	P	Info Score <sup>c</sup>
8	rs2081	8	58476	T/	0-0		T/	0-0		T/	0-0		T/	0-0		C/						
8	rs2293	8	11558	G	0-0		T/	0-0		T/	0-0		G/	0-0		G/	-0-034	2-7E-03	0-988	-0-013	1-7E-01	0-993
8	rs2737	8	11563		5-8E-11		T/	1-1E-02		T/	6-1E-01		G/	5-9E-01		C/	0-008	4-6E-01	1-000	-0-009	3-2E-01	0-983
8	rs2954	8	12547	A/	0-0		A/	0-0		A/	0-0		A/	0-0		T/	-0-036	3-0E-03	0-955	-0-012	2-4E-01	0-970
8	rs1113	8	14396	T/	0-0		A/	0-0		A/	0-0		A/	0-0		G/	0-012	2-9E-01	0-922	0-018	5-0E-02	1-000
8	rs3780	8	26407	A/	0-0		G	0-0		A/	0-0		G	0-0		G/	0-027	2-8E-02	0-834	0-008	3-9E-01	1-000
8	rs5810	9	15305	A/	0-0		A/	0-0		G/	0-0		A/	0-0		C/	-0-020	4-6E-01	0-632	-0-027	1-3E-01	1-000
8	rs1883	9	10490	C/	0-0		C/	0-0		C/	0-0		C/	0-0		T/	-0-006	6-6E-01	0-914	0-004	7-3E-01	1-000
8	rs9411	9	13327	C/	0-0		C/	0-0		C/	0-0		C/	0-0		T/	-0-030	1-6E-02	1-000	-0-012	2-4E-01	1-000
9	rs1832	9	52128	T/	0-0		T/	0-0		C/	0-0		T/	0-0		G/	0-074	3-0E-07	0-879	0-032	4-3E-03	1-000
9	rs1090	10	17218	A/	0-0		A/	0-0		A/	0-0		A/	0-0		G/	0-027	6-7E-02	1-000	0-021	9-4E-02	0-999
9	rs9705	10	45517	G/	0-0		G/	0-0		G/	0-0		G	0-0		C/	0-019	1-0E-01	0-861	0-003	7-7E-01	0-995
9	rs1076	10	63267	C/	0-0		C/	0-0		C/	0-0		C/	0-0		T/	0-004	7-6E-01	1-000	0-028	8-4E-03	0-999
9	rs2068	10	93079	T/	0-0		T/	0-0		A/	0-0		T/	0-0		A/	-0-023	3-4E-02	0-996	-0-008	3-5E-01	0-998
9		10		A/	0-0		G/	0-0		G	0-0		G/	0-0			-0-021	5-7E-02	1-000	0-001	8-8E-01	1-000

N	Varia	C	Hg38 Locati	Global Lipids Genetics Consortium <sup>a</sup>									Breast Cancer Association Consortium									
				HDL-C			LDL-C			TG			TC			iCOGS <sup>b</sup>			OncoArray			
				E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	Info Score <sup>c</sup>	$\beta$	P	Info Score <sup>c</sup>
			11217																			
	rs2255				0-0			0-0		0-0		0-0		0-0								
9		10		A/		3-0E-07	A/		2-2E-09	G/		2-8E-03	A/		2-0E-10	G/	0-006	6-3E-01	0-962	0-014	1-6E-01	0-987
	rs2923		10367		0-0			0-0		0-0		0-0		0-0								
9		11		A/		4-6E-08	G/		4-2E-02	G/		2-5E-02	A/		9-9E-01	C/	-0-033	3-1E-02	0-792	0-010	4-1E-01	1-000
	rs1012		18611		0-0			0-0		0-0		0-0		0-0								
9		11		C/		2-1E-01	C/		2-9E-07	C/		4-1E-02	C/		2-6E-08	C/	0-023	1-1E-01	0-651	0-036	4-4E-04	0-962
	rs3136		46721		0-0			0-0		0-0		0-0		0-0								
9		11		C/		3-5E-18	T/		6-4E-01	T/		6-2E-04	C/		9-6E-02	C/	-0-005	7-5E-01	0-978	0-013	3-4E-01	1-000
	rs1124		54607		0-0			0-0		0-0		0-0		0-0								
1		11		C/		1-7E-10	C/		5-3E-01	T/		1-9E-01	C/		1-9E-02	T/	0-007	6-5E-01	1-000	0-021	1-3E-01	0-996
	rs1745		61802		0-0			0-0		0-0		0-0		0-0								
1		11		C/		2-6E-22	C/		1-8E-21	T/		5-4E-24	C/		2-9E-22	A/	-0-005	6-8E-01	0-989	-0-009	3-6E-01	1-000
	rs1280		65623		0-0			0-0		0-0		0-0		0-0								
1		11		A/		3-1E-08	A/		1-4E-01	G/		1-3E-05	A/		2-6E-02	A/	-0-002	8-6E-01	0-991	-0-017	1-2E-01	1-000
	rs4999		75743		0-0			0-0		0-0		0-0		0-0								
1		11		C/		1-1E-08	A/		8-3E-01	C/		5-4E-02	C/		8-0E-04	C/	-0-028	4-5E-02	0-993	-0-012	3-2E-01	1-000
	rs9641		11677		0-1		G	0-0		G	0-2		G	0-1								
1		11		C/		5-2E-47			1-5E-26			6-7E-240			6-2E-57	C/	-0-010	5-5E-01	0-972	0-030	2-2E-02	1-000
	rs1160		11861		0-0			0-0		0-0		0-0		0-0								
1		11		T/		2-3E-03	T/		1-5E-05	T/		5-7E-01	T/		1-2E-08	C/	-0-017	1-8E-01	0-717	0-010	2-6E-01	1-000
	rs7941		12265		0-0			0-0		0-0		0-0		0-0								
1		11		C/		2-7E-08	C/		3-5E-06	T/		9-8E-01	C/		1-5E-10	A/	0-001	9-7E-01	0-671	0-018	5-8E-02	0-988
	rs1122		12637		0-0			0-0		0-0		0-0		0-0								
1		11		G/		3-1E-02	A/		1-2E-15	A/		1-7E-02	A/		5-6E-11	G/	-0-005	7-7E-01	0-841	-0-015	2-5E-01	0-990
	rs4883		89299		0-0			0-0		0-0		0-0		0-0								
1		12		A/		1-0E-03	A/		6-8E-06	A/		3-7E-01	A/		1-7E-09	A/	-0-011	6-0E-01	0-831	-0-005	7-3E-01	0-980
	rs7134		20320		0-0			0-0		0-0		0-0		0-0								
1		12		A/		3-8E-08	C/		6-7E-01	C/		8-3E-04	A/		9-5E-01	A/	0-003	7-7E-01	0-931	0-009	3-1E-01	0-963

N	Varia	C	Hg38 Locati	Global Lipids Genetics Consortium <sup>a</sup>												Breast Cancer Association Consortium						
				HDL-C			LDL-C			TG			TC			iCOGS <sup>b</sup>			OncoArray		Info Score <sup>c</sup>	
				E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	Info Score <sup>c</sup>			
1	rs1161		57398	T/	<b>0-0</b>		C/	0-0		C/	<b>0-0</b>		C/	0-0		T/						
1	rs7134	12	10956	T/	<b>4-4E-08</b>		C/	5-0E-04		C/	<b>4-4E-10</b>		C/	3-5E-03		T/	0-032	5-1E-02	0-654	0-010	3-5E-01	1-000
1	rs1106	12	11163	T/	<b>6-9E-15</b>		T/	5-6E-01		T/	6-1E-01		T/	1-3E-04		G/	-0-001	9-4E-01	0-997	-0-018	4-8E-02	1-000
1	rs1169	12	12097	A/	0-0		A/	5-8E-04		G/	8-7E-01		A/	<b>6-8E-12</b>		C/	-0-026	1-6E-02	1-000	-0-025	5-2E-03	1-000
1	rs4759	12	12331	C/	0-0		C/	1-6E-02		C/	4-6E-01		C/	<b>1-5E-14</b>		T/	-0-028	1-9E-02	0-956	-0-015	1-3E-01	0-968
1	rs4765	12	12397	T/	<b>0-0</b>		T/	7-5E-09		C/	1-2E-01		T/	6-2E-03		T/	0-025	3-0E-01	0-537	-0-009	6-0E-01	0-922
1	rs8388	12	12477	T/	<b>0-0</b>		G/	9-4E-04		G	<b>0-0</b>		G/	0-0		T/	0-011	4-1E-01	0-716	0-009	3-5E-01	0-998
1	rs4942	12	32379	C/	<b>0-0</b>		T/	4-2E-01		T/	8-0E-01		C/	3-1E-02		C/	0-012	4-5E-01	0-534	-0-014	1-5E-01	0-997
1	rs8017	13	24414	C/	0-0		T/	1-2E-04		T/	2-4E-02		T/	7-1E-08		A/	-0-026	1-7E-02	1-000	-0-013	1-5E-01	1-000
1	rs4983	14	10481	G/	0-0		A/	7-7E-01		A/	6-9E-01		A/	1-1E-07		A/	-0-042	4-0E-03	0-570	0-004	6-9E-01	1-000
1	rs2412	14	42391	G	<b>0-0</b>		G/	9-6E-09		A/	0-0		G/	0-0		A/	-0-018	1-0E-01	1-000	-0-015	9-5E-02	1-000
1	rs2929	15	43953	G/	0-0		G/	6-2E-05		A/	3-1E-01		A/	9-6E-01		T/	-0-033	3-3E-01	0-681	0-002	9-6E-01	1-000
1	rs1532	15	58391	A/	0-0		A/	2-9E-06		T/	7-7E-01		T/	6-4E-01		G/	-0-061	1-9E-02	0-965	-0-021	3-1E-01	0-999
1	rs2652	15	63104	A/	<b>0-1</b>		A/	2-9E-96		A/	0-0		A/	<b>0-0</b>		G/	-0-008	5-0E-01	0-831	-0-001	9-2E-01	1-000
1		15		G	<b>0-0</b>		G/	8-7E-09		A/	0-0		G/	0-0		G/	-0-004	7-9E-01	0-990	0-008	4-6E-01	0-994
		15			<b>8-7E-09</b>			3-7E-01			3-2E-04			4-3E-02			-0-004	7-9E-01	0-990	0-008	4-6E-01	0-994



N	Varia	C	Hg38 Locati	Global Lipids Genetics Consortium <sup>a</sup>												Breast Cancer Association Consortium							
				HDL-C			LDL-C			TG			TC			iCOGS <sup>b</sup>			OncoArray				
				E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	Info Score <sup>c</sup>	$\beta$	P	Info Score <sup>c</sup>	
1	rs3198		15036	T/	0-0		T/	0-0		C/	0-0		T/	0-0		T/							
		16				3-3E-05				6-9E-03					2-7E-01		G/	0-004	8-1E-01	0-465	-0-019	3-6E-02	0-973
1	rs1164		30907	G/	0-0		C/	0-0		C/	0-0		C/	0-0									
		16				1-9E-03				1-4E-02					2-0E-02		A/	-0-003	7-8E-01	1-000	0-024	9-9E-03	0-950
1	rs1121		53775	G	0-0		A/	0-0		A/	0-0		G/	0-0									
		16				6-8E-09				8-2E-01					1-2E-01		A/	-0-065	2-7E-09	0-999	-0-054	2-4E-09	1-000
1	rs3764		56959	A/	0-2		C/	0-0		C/	0-0		A/	0-0									
		16				0-0E+00				1-6E-12					6-7E-14		A/	0-020	7-9E-02	1-000	0-010	3-1E-01	0-996
1	rs1694		67894	A/	0-0		A/	0-0		G/	0-0		A/	0-0									
		16				8-4E-33				4-3E-01					7-6E-06		A/	0-036	2-6E-02	0-991	0-011	4-2E-01	1-000
1	rs2000		72074	G/	0-0		A/	0-0		A/	0-0		A/	0-0									
		16				5-3E-01				1-8E-22					3-2E-24		C/	-0-023	8-3E-02	1-000	0-000	1-0E+00	0-995
1	rs2925		81501	C/	0-0		T/	0-0		T/	0-0		C/	0-0									
		16				2-1E-11				9-5E-01					4-9E-01		C/	-0-002	8-9E-01	0-940	0-015	1-4E-01	1-000
1	rs3142		71883	C/	0-0		T/	0-0		T/	0-0		T/	0-0									
		17				3-5E-01				3-4E-10					3-0E-02		C/	-0-004	7-5E-01	1-000	0-022	2-2E-02	1-000
1	rs1186		39657	C/	0-0		C/	0-0		G/	0-0		C/	0-0									
		17				1-3E-13				1-5E-01					2-6E-04		C/	0-016	1-6E-01	0-970	0-005	6-0E-01	1-000
1	rs8077		43800	A/	0-0		C/	0-0		C/	0-0		A/	0-0									
		17				1-5E-06				9-2E-01					7-4E-01		A/	0-012	4-0E-01	0-913	-0-013	2-6E-01	0-984
1	rs7206		47347	A/	0-0		A/	0-0		G/	0-0		A/	0-0									
		17				1-7E-03				1-5E-08					1-0E-08		C/	0-019	9-0E-02	0-974	0-003	7-2E-01	1-000
1	rs1801		66214	A/	0-0		C/	0-1		A/	0-0		C/	0-0									
		17				8-5E-03				9-8E-12					3-4E-05		G/	0-027	4-3E-01	0-611	0-017	4-9E-01	1-000
1	rs4148		68879	C/	0-0		G/	0-0		G/	0-0		G/	0-0									
		17				1-8E-10				4-4E-03					4-9E-01		A/	-0-026	6-2E-02	0-672	-0-010	2-8E-01	0-990
1	rs4129		78407	A/	0-0		A/	0-0		G/	0-0		A/	0-0									
		17				7-6E-09				5-0E-01					1-7E-02		T/	0-002	8-3E-01	0-845	-0-004	6-3E-01	0-985
1	rs7241		49634	T/	0-0		T/	0-0		G/	0-0		T/	0-0									
		18				2-7E-49				3-2E-04					6-3E-19			0-019	1-9E-01	0-945	0-006	6-3E-01	1-000

N	Varia	C	Hg38 Locati	Global Lipids Genetics Consortium <sup>a</sup>												Breast Cancer Association Consortium						
				HDL-C			LDL-C			TG			TC			iCOGS <sup>b</sup>			OncoArray			
				E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	Info Score <sup>c</sup>	$\beta$	P	Info Score <sup>c</sup>
1	rs1296		60181	G	0-0		G/	0-0		A/	0-0		G/	0-0		A/						
1	rs7248	18	72244		<b>6-6E-09</b>		G/	8-1E-01		A/	1-4E-05		G/	4-1E-01		A/	-0-024	6-0E-02	0-994	-0-012	2-4E-01	0-999
1	rs7255	19	83683	A/	0-0		G/	0-0		G	<b>0-0</b>		G/	0-0		A/	-0-012	3-6E-01	0-690	-0-007	4-7E-01	0-996
1	rs6511	19	11091	A/	<b>0-0</b>		A/	0-0		C/	0-0		A/	0-0		A/	-0-012	3-6E-01	0-690	-0-007	4-7E-01	0-996
1	rs7373	19	11236	T/	0-0		G	<b>0-2</b>		G/	0-0		G	<b>0-1</b>		T/	-0-013	3-4E-01	0-620	0-006	5-3E-01	0-982
1	rs1040	19	19296	T/	0-0		T/	0-0		G/	0-0		T/	0-0		C/	0-008	7-1E-01	0-674	0-019	1-9E-01	1-000
1	rs7318	19	33408	C/	0-0		T/	<b>0-1</b>		T/	<b>0-1</b>		T/	<b>0-1</b>		A/	-0-034	2-1E-01	0-369	-0-004	8-0E-01	1-000
1	rs4394	19	44911	A/	0-0		A/	0-0		G	<b>0-0</b>		A/	0-0		A/	0-029	1-5E-01	0-971	0-022	1-8E-01	1-000
1	rs4420	19	44919	T/	0-0		C/	0-0		C/	<b>0-0</b>		C/	0-0		C/	-0-025	4-3E-02	0-843	-0-013	1-8E-01	1-000
1	rs4926	19	48703	A/	0-0		G	<b>0-2</b>		G/	0-0		G	<b>0-1</b>		G/	-0-003	7-8E-01	1-000	-0-031	1-0E-03	1-000
1	rs1769	19	51820	G	<b>0-0</b>		G/	0-0		A/	0-0		G/	0-0		A/	0-017	1-3E-01	0-951	0-008	3-5E-01	0-998
1	rs3860	19	54288	C/	0-0		C/	0-0		G/	0-0		C/	0-0		C/	-0-023	9-4E-02	0-830	0-002	8-7E-01	1-000
1	rs3645	19	12982	G/	0-0		G	<b>0-0</b>		A/	0-0		G/	0-0		G/	0-012	3-7E-01	0-989	-0-031	9-3E-03	0-878
1	rs2328	20	17865	A/	0-0		C/	<b>0-0</b>		A/	0-0		C/	0-0		C/	0-017	2-0E-01	0-670	-0-005	5-8E-01	0-997
1	rs2277	20	35564	C/	0-0		C/	0-0		A/	0-0		C/	<b>0-0</b>		T/	0-004	8-6E-01	0-353	-0-017	1-4E-01	1-000
1		20		C/	0-0		C/	0-0		C/	0-0		C/	<b>0-0</b>		T/	-0-001	9-7E-01	1-000	0-009	5-0E-01	1-000

N	Varia	C	Hg38 Locati	Global Lipids Genetics Consortium <sup>a</sup>												Breast Cancer Association Consortium						
				HDL-C			LDL-C			TG			TC			iCOGS <sup>b</sup>			OncoArray		Info Score <sup>c</sup>	
				E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	E/	$\beta$	P	$\beta$	P		
1	rs2902		40462		0-0		<b>0-0</b>		0-0		<b>0-0</b>		0-0		<b>0-0</b>	G/						
		20		A/	5-2E-01		<b>1-6E-08</b>		2-5E-03		<b>6-1E-11</b>		0-008	5-3E-01	0-923	A/	-0-002	8-6E-01	1-000			
1	rs6029		41043		0-0		<b>0-0</b>		0-0		<b>0-0</b>		0-003	7-7E-01	0-947	T/	0-007	4-4E-01	0-994			
		20		T/	8-7E-01		<b>3-7E-19</b>		1-2E-02		<b>8-5E-17</b>		0-003	7-7E-01	0-947	T/	0-007	4-4E-01	0-994			
1	rs1800		44413		<b>0-1</b>		0-0		0-0		<b>0-1</b>		-0-025	4-0E-01	1-000	C/	-0-038	1-4E-01	1-000			
		20		C/	<b>1-1E-15</b>		2-4E-05		5-9E-01		<b>5-7E-13</b>		-0-025	4-0E-01	1-000	C/	-0-038	1-4E-01	1-000			
1	rs6065		45925		<b>0-0</b>		0-0		<b>0-0</b>		0-0		-0-013	3-6E-01	0-947	C/	-0-021	7-7E-02	1-000			
		20		T/	<b>1-9E-22</b>		3-0E-01		<b>2-6E-17</b>		9-7E-01		-0-013	3-6E-01	0-947	T/	-0-021	7-7E-02	1-000			
1	rs1813		21577		<b>0-0</b>		0-0		0-0		<b>0-0</b>		-0-011	4-1E-01	0-977	C/	0-015	1-9E-01	0-999			
		22		C/	<b>1-1E-08</b>		8-3E-02		2-3E-02		2-8E-05		-0-011	4-1E-01	0-977	C/	0-015	1-9E-01	0-999			
1	rs5763		29982		0-0		<b>0-0</b>		0-0		0-0		-0-030	4-3E-01	0-956	T/	-0-048	1-2E-01	0-998			
		22		T/	6-4E-03		<b>1-2E-08</b>		8-9E-01		7-7E-08		-0-030	4-3E-01	0-956	T/	-0-048	1-2E-01	0-998			
1	rs1387		35315		0-0		0-0		0-0		<b>0-0</b>		-0-016	3-3E-01	0-439	G/	0-010	3-1E-01	0-981			
		22		A/	8-9E-02		4-9E-06		3-8E-01		<b>4-7E-08</b>		-0-016	3-3E-01	0-439	G/	0-010	3-1E-01	0-981			
1	rs5756		38150		0-0		0-0		<b>0-0</b>		0-0		-0-037	9-6E-04	1-000	C/	-0-049	1-4E-07	0-989			
		22		C/	4-3E-03		1-8E-02		<b>3-8E-08</b>		8-3E-03		-0-037	9-6E-04	1-000	C/	-0-049	1-4E-07	0-989			
1	rs4253		46231		0-0		<b>0-0</b>		0-0		<b>0-0</b>		-0-030	8-8E-02	0-998	T/	-0-018	2-2E-01	0-989			
		22		C/	9-1E-01		<b>4-3E-08</b>		5-8E-04		<b>9-9E-09</b>		-0-030	8-8E-02	0-998	T/	-0-018	2-2E-01	0-989			

<sup>a</sup> Summary statistics for each GWAS-identified variant with high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), triglycerides (TG), and total cholesterol (TC) from the Global Lipids Genetics Consortium, representing a standard deviation (SD) increase in each lipid trait. Effect alleles correspond to an increase in each lipid trait (i.e., E/R = effect allele/reference allele), and were ascertained from Table 1 of Teslovich et al., 2010, and Tables 1-4 of Willer et al., 2013. Variants included in specific lipid genetics scores are in **bold** (HDL-C: 74 variants; LDL-C: 57 variants; TG: 43 variants; TC: 74 variants).

<sup>b</sup> Summary statistics for BCAC iCOGS exclude 19,018 individuals that overlap with BCAC OncoArray.

<sup>c</sup> Information score for 123 imputed variants and 39 genotyped variants in BCAC iCOGS (average information score = 0.82). Information score for 87 imputed variants and 75 genotyped variants in BCAC OncoArray (average information score = 0.98).

**Supplementary Table 2.** Associations between genetically predicted lipid trait levels and breast cancer risk factors using individual-level data from the Breast Cancer Association Consortium

Breast cancer risk factor	N	Mean (SD) or %	High density lipoprotein (HDL-C) wGS <sup>a</sup>			Low density lipoprotein (LDL-C) wGS <sup>a</sup>			Triglycerides (TG) wGS <sup>a</sup>			Total cholesterol (TC) wGS <sup>a</sup>		
			B <sup>b</sup>	SE <sup>b</sup>	P	B <sup>b</sup>	SE <sup>b</sup>	P	B <sup>b</sup>	SE <sup>b</sup>	P	B <sup>b</sup>	SE <sup>b</sup>	P
<b>BCAC iCOGS</b>														
Age <sup>c</sup>	75 624	56.6 (11.1)	0.25	0.15	0.11	-0.51	0.16	1.1x10 <sup>-3</sup>	-0.64	0.18	4.0x10 <sup>-4</sup>	-0.65	0.15	1.1x10 <sup>-5</sup>
Age at menarche	46 338	13.1 (1.6)	0.04	0.03	0.19	-0.04	0.03	0.21	-0.03	0.03	0.29	-0.04	0.03	0.13
Age at menopause	22 486	48.7 (5.8)	-0.04	0.15	0.80	-0.07	0.15	0.65	-0.29	0.18	0.10	-0.22	0.14	0.13
Age at first live birth <sup>d</sup>	38 483	25.2 (4.9)	0.11	0.10	0.25	-0.02	0.10	0.82	-0.35	0.11	1.6x10 <sup>-3</sup>	-0.14	0.09	0.12
Number of births <sup>d</sup>	45 149	2.3 (1.0)	-0.01	0.02	0.74	0.01	0.02	0.78	0.01	0.02	0.85	-0.01	0.02	0.79
BMI (Premenopausal Women)	11 249	25.2 (4.9)	-0.21	0.18	0.23	-0.14	0.18	0.44	0.05	0.21	0.80	-0.17	0.17	0.32
BMI (Postmenopausal Women)	27 206	26.3 (4.8)	0.02	0.11	0.85	-0.10	0.11	0.39	-0.05	0.13	0.72	-0.03	0.11	0.76
Ever breastfed <sup>d</sup>	24 028	82.4%	0.15	0.06	1.2x10 <sup>-2</sup>	0.03	0.06	0.57	-0.30	0.07	1.6x10 <sup>-5</sup>	-0.13	0.06	0.02
Ever smoked regularly	15 993	45.9%	0.01	0.04	0.94	-0.05	0.04	0.21	-0.01	0.05	0.93	-0.06	0.04	0.13
Family history of breast cancer	8 953	28.1%	0.06	0.05	0.17	-0.01	0.05	0.82	-0.05	0.05	0.40	0.01	0.04	0.82
<b>BCAC OncoArray</b>														
Age <sup>c</sup>	106 053	55.8 (11.7)	0.10	0.13	0.47	-0.23	0.13	0.08	-0.21	0.16	0.18	-0.32	0.12	0.01
Age at menarche	74 572	13.0 (1.6)	0.05	0.02	9.6x10 <sup>-3</sup>	0.01	0.02	0.85	-0.06	0.02	0.02	-0.01	0.02	0.64
Age at menopause	39 451	48.6 (5.8)	0.04	0.11	0.71	-0.13	0.10	0.21	0.07	0.13	0.58	-0.09	0.10	0.39
Age at first live birth <sup>d</sup>	59 688	25.2 (4.8)	-0.01	0.07	0.95	0.04	0.07	0.62	-0.12	0.08	0.14	-0.04	0.07	0.59
Number of births <sup>d</sup>	66 678	2.3 (1.1)	0.03	0.02	0.10	-0.03	0.01	0.04	-0.01	0.02	0.53	-0.01	0.01	0.42
BMI (Premenopausal Women)	22 797	25.4 (5.1)	0.02	0.12	0.85	-0.08	0.12	0.52	0.21	0.14	0.14	-0.01	0.12	0.96
BMI (Postmenopausal Women)	47 121	26.6 (5.1)	0.04	0.09	0.65	-0.05	0.08	0.58	0.26	0.10	0.01	0.07	0.08	0.40
Ever breastfed <sup>d</sup>	36 224	78.5%	0.05	0.04	0.25	0.02	0.04	0.55	-0.07	0.05	0.13	-0.01	0.04	0.97
Ever smoked regularly	30 183	46.2%	-0.01	0.03	0.99	-0.02	0.03	0.45	-0.04	0.03	0.20	-0.05	0.03	0.09
Family history of breast cancer	18 071	26.6%	-0.01	0.03	0.96	-0.01	0.03	0.64	0.02	0.04	0.58	0.01	0.03	0.62

<sup>a</sup> Genetically predicted lipid traits levels from weighted-genetic scores (wGSs).

<sup>b</sup> Beta estimates (β) and corresponding standard deviations (SD) estimated using either linear or logistic regression for continuous or dichotomous risk factors, respectively. Estimates represent associations per 1 SD increase in lipid trait.

<sup>c</sup> Age at diagnosis for cases, or age at interview for controls. Mean values used for subjects with missing information in regression models.

<sup>d</sup> Among parous women.

**Supplementary Table 3.** Association between one standard deviation (SD) increase in genetically-predicted lipid traits and breast cancer risk using individual-level data in the Breast Cancer Association Consortium (BCAC) for different covariate adjustment sets by genotyping platform

Genotyping Platform	Cases	Controls	High density lipoprotein (HDL-C) wGS <sup>a</sup>			Low density lipoprotein (LDL-C) wGS <sup>a</sup>			Triglycerides (TG) wGS <sup>a</sup>			Total cholesterol (TC) wGS <sup>a</sup>		
			OR	95% CI	P	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P
<b>No adjustment</b>														
iCOGS <sup>b</sup>	38 578	37 046	1.14	1.08-1.21	2.3x10 <sup>-6</sup>	1.01	0.95-1.06	0.85	1.03	0.96-1.09	0.43	1.10	1.04-1.16	3.4x10 <sup>-4</sup>
OncoArray <sup>c</sup>	62 846	43 207	1.07	1.02-1.12	5.5x10 <sup>-3</sup>	0.99	0.95-1.03	0.65	1.00	0.95-1.05	0.95	1.06	1.01-1.10	1.1x10 <sup>-2</sup>
<b>Minimally-adjusted<sup>d</sup></b>														
iCOGS <sup>b</sup>	38 578	37 046	1.14	1.08-1.21	6.6x10 <sup>-6</sup>	1.01	0.95-1.07	0.80	0.97	0.90-1.03	0.31	1.08	1.02-1.14	9.6x10 <sup>-3</sup>
OncoArray <sup>c</sup>	62 846	43 207	1.10	1.05-1.16	4.3x10 <sup>-5</sup>	0.99	0.95-1.04	0.77	0.89	0.85-0.94	5.8x10 <sup>-5</sup>	1.02	0.97-1.06	0.43
<b>Multivariable</b>														
iCOGS <sup>b</sup>														
All women <sup>e</sup>	38 578	37 046	1.14	1.07-1.21	1.1x10 <sup>-5</sup>	1.01	0.95-1.07	0.87	0.98	0.91-1.04	0.48	1.08	1.02-1.14	7.3x10 <sup>-3</sup>
Among parous women <sup>f</sup>	13 063	12 503	1.16	1.05-1.28	4.6x10 <sup>-3</sup>	0.97	0.88-1.07	0.56	0.94	0.83-1.06	0.30	1.02	0.93-1.13	0.62
OncoArray <sup>c</sup>														
All women <sup>e</sup>	40 165	29 789	1.11	1.04-1.17	6.2x10 <sup>-4</sup>	1.00	0.94-1.06	0.94	0.89	0.83-0.95	6.6x10 <sup>-4</sup>	1.02	0.96-1.07	0.58
Among parous women <sup>f</sup>	33 469	25 732	1.11	1.04-1.18	1.6x10 <sup>-3</sup>	1.01	0.95-1.07	0.81	0.90	0.83-0.97	3.9x10 <sup>-3</sup>	1.02	0.96-1.08	0.51

<sup>a</sup> Number of variantss included in lipid-specific weighted-genetic score (wGS): HDL-C = 74, LDL-C = 57, TG = 43, and TC = 74.

<sup>b</sup> Associations between each lipid-specific wGS and breast cancer risk are estimated from an unconditional logistic regression model adjusted for age, study, and top 6 principal components for European ancestry in the iCOGS sample. The iCOGS analysis excludes 19 018 individuals that overlap with OncoArray.

<sup>c</sup> Associations between each lipid-specific wGS and breast cancer risk are estimated from an unconditional logistic regression model adjusted for age, country, and top 10 principal components for European ancestry in the OncoArray sample.

<sup>d</sup> Models adjusted for age, study (iCOGS) or country (OncoArray), and top 6 (iCOGS) or top 10 (OncoArray) principal components for European ancestry.

<sup>e</sup> For iCOGS data, model adjusted for age, BCAC study, top 6 principal components for European ancestry, breastfeeding (ever/never), and age at first live birth (years). For OncoArray data, model adjusted for age, country, and top 10 principal components for European ancestry, age at menarche (years), parity (number of children), and body mass index (kg/m<sup>2</sup>; n=29,787 missing). Additional covariates were chosen based on results from Supplementary Table 2.

<sup>f</sup> For iCOGS data, model adjusted for age, BCAC study, top 6 principal components for European ancestry, breastfeeding (ever/never), and age at first live birth (years), among parous women only. For OncoArray data, model adjusted for age, country, and top 10 principal components for European ancestry, age at menarche (years), parity (number of children), and body mass index (kg/m<sup>2</sup>), among parous women only. Additional covariates were chosen based on results from Supplementary Table 2.



**Supplementary Table 4.** Pearson correlation coefficients among original and amended weighted-genetic scores (wGSs)

	High density lipoprotein (HDL-C) wGS		Low density lipoprotein (LDL-C) wGS		Triglycerides (TG) wGS		Total cholesterol (TC) wGS	
	Coefficient	<i>P</i>	Coefficient	<i>P</i>	Coefficient	<i>P</i>	Coefficient	<i>P</i>
<b>BCAC iCOGS</b>								
<b>All Reported Variants <sup>a</sup></b>								
HDL-C	1.00000							
LDL-C	-0.14101	<0.0001	1.00000					
TG	-0.38380	<0.0001	0.22490	<0.0001	1.00000			
TC	0.09205	<0.0001	0.85017	<0.0001	0.31386	<0.0001	1.00000	
<b>Exclusive Variants 1 <sup>b</sup></b>								
HDL-C	1.00000							
LDL-C	-0.00158	0.6629	1.00000					
TG	-0.00480	0.1866	0.00414	0.2544	1.00000			
<b>BCAC OncoArray</b>								
<b>All Reported Variants <sup>a</sup></b>								
HDL-C	1.00000							
LDL-C	-0.14516	<0.0001	1.00000					
TG	-0.38707	<0.0001	0.21194	<0.0001	1.00000			
TC	0.06973	<0.0001	0.85615	<0.0001	0.30255	<0.0001	1.00000	
<b>Exclusive Variants 1 <sup>b</sup></b>								
HDL-C	1.00000							
LDL-C	-0.00121	0.7286	1.00000					
TG	-0.01324	<0.0001	0.01167	0.0008	1.00000			

<sup>a</sup> Genetically predicted lipid traits levels from weighted-genetic scores (wGS), created by summing the number of risk alleles for each individual, weighted by beta coefficient from the Global Lipids Genetics Consortium, based on 74, 57, 43, and 74 variants for HDL-C, LDL-C, TG, and TC, respectively.

<sup>b</sup> Exclusive weighted-genetic scores for each lipid trait include only variants associated with HDL-C, LDL-C, or triglycerides at a genome-wide significance *p* value  $\leq 5 \times 10^{-8}$ . Exclusive variant weighted-genetic scores include 54, 42, and 20 variants for HDL-C, LDL-C, and triglycerides, respectively. A weighted-genetic score was not constructed for total cholesterol.

**Supplementary Table 5.** Associations between one standard deviation (SD) increase in lipid trait levels and breast cancer risk factors using summary statistics from both iCOGS and OncoArray data to estimate the inverse-variance weighted (IVW) Mendelian randomization association, and associations from three different sensitivity analyses in the Breast Cancer Association Consortium (BCAC)

Approach	Cases	Controls	High density lipoprotein (HDL-C)			Low density lipoprotein (LDL-C)			Triglycerides (TG)			Total cholesterol (TC)		
			OR	95% CI	P	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P
<b>IVW MR estimate<sup>a</sup></b>														
iCOGS	38 578	37 046	1.15	1.09-1.22	1.3x10 <sup>-6</sup>	1.00	0.95-1.06	0.93	0.96	0.89-1.03	0.22	1.06	1.01-1.12	2.7x10 <sup>-2</sup>
OncoArray	62 846	43 207	1.10	1.05-1.16	3.4x10 <sup>-5</sup>	0.99	0.94-1.03	0.58	0.88	0.83-0.92	1.9x10 <sup>-6</sup>	1.01	0.96-1.05	0.79
Meta-analysis <sup>e</sup>	101 424	80 253	1.12	1.08-1.17	1.8x10 <sup>-7</sup>	0.99	0.96-1.03	0.74	0.92	0.84-1.00	4.1x10 <sup>-1</sup>	1.03	0.99-1.08	0.18
<i>p</i> <sub>heterogeneity</sub>				0.25			0.78			5.6x10 <sup>-2</sup>			0.17	
<b>Egger regression<sup>b</sup></b>														
iCOGS	38 578	37 046	1.07	0.95-1.21	0.26	0.94	0.81-1.09	0.42	0.96	0.80-1.15	0.64	0.91	0.79-1.04	0.17
OncoArray	62 846	43 207	1.05	0.94-1.17	0.40	0.95	0.86-1.05	0.29	0.89	0.77-1.03	0.12	0.93	0.84-1.03	0.16
Meta-analysis <sup>e</sup>	101 424	80 253	1.06	0.98-1.15	0.17	0.95	0.87-1.03	0.20	0.92	0.82-1.03	0.13	0.92	0.85-1.00	5.5x10 <sup>-2</sup>
<i>p</i> <sub>heterogeneity</sub>				0.82			0.91			0.52			0.80	
<b>Weighted-regression<sup>c</sup></b>														
iCOGS	38 578	37 046	1.16	1.08-1.25	2.6x10 <sup>-5</sup>	1.03	0.96-1.10	0.44	0.97	0.88-1.07	0.57	1.62	0.43-6.01	0.47
OncoArray	62 846	43 207	1.05	0.99-1.11	8.9x10 <sup>-2</sup>	1.03	0.98-1.08	0.24	0.88	0.81-0.95	1.1x10 <sup>-3</sup>	1.52	0.55-4.21	0.42
Meta-analysis <sup>e</sup>	101 424	80 253	1.10	1.00-1.21	5.4x10 <sup>-2</sup>	1.03	0.99-1.07	0.14	0.92	0.84-1.01	8.5x10 <sup>-2</sup>	1.56	0.70-3.48	0.28
<i>p</i> <sub>heterogeneity</sub>				3.5x10 <sup>-2</sup>			0.99			0.13			0.94	
<b>Weighted-median<sup>d</sup></b>														
iCOGS	38 578	37 046	1.09	1.02-1.17	1.3x10 <sup>-2</sup>	0.92	0.80-1.05	0.21	1.00	0.91-1.11	0.96	1.01	0.86-1.17	0.95
OncoArray	62 846	43 207	1.05	0.95-1.15	0.33	0.96	0.83-1.11	0.59	0.87	0.80-0.94	4.9x10 <sup>-4</sup>	1.01	0.86-1.17	0.94
Meta-analysis <sup>e</sup>	101 424	80 253	1.08	1.02-1.14	9.4x10 <sup>-3</sup>	0.94	0.85-1.04	0.21	0.93	0.81-1.07	0.30	1.01	0.91-1.13	0.86
<i>p</i> <sub>heterogeneity</sub>				0.52			0.68			3.3x10 <sup>-2</sup>			0.99	

<sup>a</sup> Mendelian randomization estimate derived using summary statistics for both iCOGS and OncoArray datasets.<sup>25</sup>

<sup>b</sup> Mendelian randomization estimate accounting for potential directional pleiotropy of genetic variants used in the instrument.<sup>26</sup> For iCOGS, intercept and *p* values for each lipid are as follows: (1) HDL-C:  $\beta_{intercept} = 0.0052$ ,  $p=0.11$ ; (2) LDL-C:  $\beta_{intercept} = 0.0049$ ,  $p=0.30$ ; (3) TG:  $\beta_{intercept} = -0.0001$ ,  $p=0.99$ ; and (4) TC:  $\beta_{intercept} = 0.0105$ ,  $p=7.3x10^{-2}$ . For OncoArray, intercept and *p* values for each lipid are as follows: (1) HDL-C:  $\beta_{intercept} = 0.0034$ ,  $p=0.23$ ; (2) LDL-C:  $\beta_{intercept} = 0.0031$ ,  $p=0.32$ ; (3) TG:  $\beta_{intercept} = 0.0011$ ,  $p=0.80$ ; and (4) TC:  $\beta_{intercept} = 0.0053$ ,  $p=7.3x10^{-2}$ .

<sup>c</sup> Mendelian randomization estimate accounting for potential genetic pleiotropy for HDL-C, LDL-C, and TG, and estimates are mutually-adjusted for one another. TC estimate is mutually-adjusted for all three lipids.<sup>27, 28</sup>

<sup>d</sup> Mendelian randomization estimate assuming 50% of the genetic variants used in each lipid-specific instrument are invalid.<sup>29</sup> Standard error for weighted-median approach estimated via bootstrapping and used to calculate 95% CIs.



<sup>e</sup> Random-effects meta-analysis.